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Asthma is a common chronic inflammatory disease of the airways, affecting 360 million 
people globally. It is characterised by chronic inflammation, recurrent episodes of 
bronchoconstriction and mucosal hypersecretion. Symptoms include chest tightness, 
shortness of breath, coughing and wheezing. Oral corticosteroids used for the treatment 
of asthma have adverse effects, including bone mineralisation and adrenal suppression. 
Not all children with acute asthma-like symptoms will have persistent asthma in the 
future. This is particularly common at a pre-school age. This persistence is only known 
retrospectively. Identifying children early in their disease course can better direct 
treatment. Additionally, further understanding of the underlying disease mechanisms can 
direct novel therapies. 
 
Metabolomics is the systematic study of metabolites in a biological system. Metabolites 
are low molecular weight biochemical that are reactants, intermediates and end products 
of biological reactions. They are highly sensitive and are a snapshot of a particular 
biochemistry and/or pathophysiology. However, they are also highly sensitive to 
analytical variation. Thus, there were three aims in this study: to assess the impact of 
potentially limiting factors of retrospectively collected serum samples on metabolomic 
analysis; to determine whether metabolomics can identify potential biomarkers to 
distinguish wheeze/asthma exacerbation and control groups; and to determine whether 
metabolomics-derived biomarkers can identify differences between preschool-aged and 
school-aged phenotypes. 
 
Serum samples were curated from the Mechanisms of Acute Viral Respiratory Infections 
in Children (MAVRIC) study. This cohort study recruited children upon presentation to 
the emergency department at Princess Margret Hospital with acute lower respiratory 
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illnesses including wheeze/asthma. One–hundred and sixty-one samples were from 
children with acute wheeze/asthma, and 51 were from healthy controls. Samples were 
previously stored between 0.8 to 7.9 years at −80 °C. Samples were extracted, derivatised 
and subsequently analysed using GC-QTOF-MS. SpectralWorks’ AnalyzerPro® was 
used for the deconvolution and untargeted processing of the metabolite data. The quality 
control-robust spline correction (QC-RSC) algorithm was used for inter- and intra-  batch 
correction. Putative identification of metabolites was made using the NIST (v2.0) library.  
 
Fifty-two metabolites were included in the data analysis, with 24 putatively identified 
metabolites. The effects of storage time on metabolites were determined via Spearman’s 
correlation. There was a significant difference (p-value < 0.05) in metabolite abundances 
for succinate, serine and tryptophan; however, the correlation was weak. A two-way 
Analysis of Variance was performed to compare acute wheeze/asthma vs. healthy,         
pre-school vs. school age and the associated interactions. Twenty-nine metabolites were 
found to be significantly different (p-value < 0.05) between the acute wheeze/asthma and 
the control group. The sub-classes of metabolites include amino acids, fatty acids and 
sugars. Principal Component Analysis showed a difference in spread between the acute 
wheeze/asthma and control group. However, there was no clear difference between 
preschool and school-aged brackets for each group. Arabinofuranose and creatinine were 
significantly different (p-value < 0.05) between pre-school and school-aged subjects with 
acute wheeze/asthma. Creatinine is potentially being indicative of higher ASM stress and 
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Chapter One: Literature Review 
 
1.1. Asthma 
Asthma is a common chronic inflammatory disease of the airways, with a global 
prevalence of 358 million in 2015 (Vos et al. 2016). Chronic inflammation leads to airway 
restriction through bronchoconstriction, mucosal hypersecretion and airway remodelling 
(Martinez and Vercelli 2013). Airway restriction during asthmatic symptoms is shown in 
Figure 1.1.  It is characterised by recurrent episodes of chest tightness, shortness of breath, 
coughing and wheezing (Bousquet et al. 2000). These episodes are referred to as acute 
asthma, asthma attacks or asthma exacerbations. Morbidity of asthma is high due to the 
chronic health conditions and treatment side effects (Aagaard and Hansen 2014).  There 
is also a high financial burden on individuals, families and public health systems with an 
estimated cost of $1.2 billion to Australians in 2015 (Deloitte 2015). Despite the high 
prevalence and burden, there is no current cure for asthma while treatment options remain 
limited. The major barrier to developing new management strategies is the heterogeneity 










Figure 1.1: A; anatomical position of the airways and lungs. B; section of a normal 
airway. C; section of an airway during asthmatic symptoms. Reproduced from the 
National Heart, Lung and Blood Institute (2014). 
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1.1.1. Definitions 
Due to the heterogeneity of asthma, there is a lack of a concise definition. The most 
widely accepted definition is by the Global Initiative for Asthma (GINA): 
 
“Asthma is a heterogeneous disease, usually characterized by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that vary over time and in intensity, 
together with variable expiratory airflow limitations.” (Global Initiative for 
Asthma 2017, 14)  
 
This definition is based on common symptoms and identifies the heterogeneous nature of 
asthma. It does not address underlying pathogenic mechanisms or associated endotypes 
of asthma (Fahy 2015). The lack of clear definition is further complicated by diagnosis, 
which is based on a physical examination and lung function test (Franzese 2015). 
Misdiagnosis is a major issue due to symptoms being shared with other lower respiratory 
conditions (Heffler et al. 2015). Furthermore, treatment is based on resolving acute 
symptoms by using non-specific asthma medication, which is ineffective for 5% of 
patients (Barnes and Woolcock 1998). An improved definition encompassing underlying 
pathogenic mechanisms and classification of asthma endotypes is needed to develop 
novel treatment options. 
 
1.1.2. Pathophysiology 
Asthma symptoms arise from variable airway obstruction in the bronchi and bronchioles 
during an inflammatory response to stimuli (Burgel et al. 2009). Bronchoconstriction, 
mucosal hypersecretion and airway remodelling mediate varying levels of airway 
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obstruction (Bousquet et al. 2000). The combination of these processes account for the 
episodic and long-term symptoms associated with asthma.  
 
1.1.2.1. Inflammation 
Inflammation is the hallmark feature of asthma with the involvement of several immune 
cell types. CD4+ T helper (Th) cells are central to adaptive immunity and play an integral 
role in asthma. Naïve CD4+ T helper cell are located in peripheral lymphoid tissue. As 
illustrated in Figure 1.2, the activation of naïve CD4+ T helper cell via antigen-presenting 
cells cause differentiation, proliferation and release of specific cytokines as interferons 
(IFN), interleukins (IL) and tumour necrosis factors (TNF) (Alberts 2002). These 
cytokines directly mediate bronchoconstriction and mucosal hypersecretion. 
Additionally, these released cytokines recruit other immune cell types including mast 
cells, eosinophils, neutrophils, dendritic cells and macrophages. These immune cell types 
can additionally mediate airway obstruction associated with asthma via various released 
inflammatory mediators. 
 
Asthma exacerbations were previously thought to be caused by Th2 differentiation, 
resulting in eosinophil recruitment via IL-5 (Cosmi et al. 2011). However, not all asthma 
present as high Th2 phenotypes (Fahy 2015, Siegle et al. 2011). Th17 mediated responses 
are also prevalent in severe forms of asthma. Th17 cells recruit neutrophils by secreting 
the chemoattractant IL-17 (Cosmi et al. 2011). Additionally, combination phenotypes 
have also been found with high levels of Th2 and Th17 cells (Aujla and Alcorn 2011, 
Cosmi et al. 2011). Thus, immune cell phenotypes and associated mediators are 




Figure 1.2: Activation and differentiation of naïve Th cell based on cytokines present at 
the time of antigen presentation by APCs. Activated Th cells secrete various cytokines as 
illustrated. The red box illustrates Th cell differentiation with established significance to 





Bronchoconstriction is the primary process associated with the airway obstruction of 
asthma exacerbations (Bousquet et al. 2000). It is caused by the short-term but rapid and 
severe response of airway smooth muscle (ASM) to stimuli (Black et al. 2012). Stimuli 
activating ASM receptors initiate down-stream signalling leading to increased 
intracellular calcium ion concentration, in turn causing bronchoconstriction via 
excitation-contraction coupling (Pelaia et al. 2008). There are multiple mediators of 
bronchoconstriction which act on various receptors (Table 1.1). Treatments have been 
developed to reduce bronchoconstriction by blocking specific receptor activation, though 
with differing levels of response (Marcello and Carlo 2016). This suggests that there is 
also heterogeneity in the pathways leading to bronchoconstriction in asthma, and 
therefore the variable response to treatment.  
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Table 1.1: Main mediators of bronchoconstriction in asthma and their corresponding 













1.1.2.3. Mucosal Hypersecretion 
Mucosal hypersecretion also contributes to airway obstruction. It is well documented that 
airway goblet cell hyperplasia and increased sputum production occur in asthma (Fahy 
2002, Rogers 2004, Evans et al. 2009, Izuhara et al. 2009). Airway goblet cells are found 
in the surface epithelium of conducting airways and secrete mucin glycoproteins; the 
major molecular constituent of epithelial mucus (Rogers 2003). Mucin glycoproteins are 
regulated by mucin genes (MUC) and form sputum in healthy individuals to trap foreign 
particles that enter the lungs during normal breathing (Davies et al. 2002). In asthmatics, 
there is airway goblet cell hyperplasia with overall increased sputum secretion. Sputum 
is also thicker due to upregulation of MUC gene expression (Evans et al. 2009). As shown 
in Table 1.2, there are numerous mediators. Levels of mucus secretion are highly variable 
amongst asthmatics. The reasons for this high variability are not fully understood (Niimi 
2011). 
Mediators Receptor 
Acetylcholine M muscarinic 
Adenosine A1 
Bradykinin BK1 
Cysteinyl leukotrienes CystLT1R 
Endothelin-1 ETA/ETB 
Histamine H1 
Prostaglandin F2α FP 





Table 1.2: Known mediators of airway mucus secretion, goblet cell hyperplasia and MUC 
synthesis/gene expression in asthma. Adapted from (Rogers 2004) with additional 
information from Kondo et al. (2008), (Yamauchi et al. 2008), Tanabe et al. (2011) and 
Lin et al. (2014). 
 
1.1.2.4. Airway Remodelling 
Airway remodelling is the tissue repair response to airway injuries caused by 
inflammation, particularly due to acute asthma exacerbations. There are numerous 
structural changes including increased ASM mass, surface epithelial metaplasia, 
angiogenesis and sub-epithelial fibrosis (Tang et al. 2006, Doherty and Broide 2007, 
Aceves and Broide 2008, Halwani et al. 2013). These structural changes are associated 
with poor clinical outcomes. The regulation of the tissue repair mechanisms are highly 
variable and not well established (Bergeron, Tulic and Hamid 2010).  This process can 
Mediators Secretion Hyperplasia MUC  
Cytokines    
IL-1B + NP NP 
IL-6 + NP + 
IL-9 NP + + 
IL-13 + + + 
TNF-𝛼𝛼 + +a +a 
IL-33 + + + 
    
Gases    
Irritant + + + 
Nitric oxide -/+ NP NP 
    
Inflammatory Mediators    
Bradykinin + NP NP 
Cysteinyl Leukotrienes + NP NP 
Endothelin 0/+ NP NP 
Histamine + + + 
Platelet-Activating Factor + +a +a 
Prostaglandins + NP NP 
Proteinases 0/+ + NP 
Purine nucleotides + NP NP 
Note: aEffects only observed with TNF-𝛼𝛼 and PAF in combination. + represents 
positive effect. – represents negative effect. 0 represents no effect. NP represents no 






lead to permanent structural changes in the airways and progressive loss of lung function, 
measurable by the reduced ability to exhale air in a forced breath (forced expiratory 
volume) (Pascual and Peters 2009). While airway remodelling occurs throughout an 
individual’s life, some studies have shown it can begin in early childhood (Grol et al. 
1999, Bai et al. 2000, Saglani et al. 2007, Lezmi et al. 2015). Airway remodelling is also 
a normal part of growth so the effects of airway remodelling in children remain 
controversial. Airway remodelling has no distinct mechanisms, rather it encompasses 
various types of permanent structural changes. The high complexity and variability have 
resulted in the lack of treatment focused on repairing airway remodelling.   
 
1.1.3. Aetiology 
Aetiology is rarely described in asthma definitions. This combination of complex and 
partially understood genetic and environmental interactions makes it challenging to 
isolate specific causes (Ober and Vercelli 2011). These factors and their interactions 
influence both the progression of asthma and severity of symptoms.  
 
1.1.3.1. Genetic Predisposition 
Familial hierarchical clustering and twin studies have shown the strong heritable genetic 
components of asthma, with heritable estimates between 35% and 95% (Burke et al. 2003, 
Ober 2011, Thomsen 2014). Known functional changes due to genetic variations include 
increased sputum production and increased receptor expression of high-affinity 
immunoglobulin E receptor β on mast cells (Cookson 2004). Genome-wide associated 
studies have found more than 100 loci harbouring variations associated with asthma 
(Bossé and Hudson 2006, Vercelli 2008). The function of all the genes associated with 
asthma are still unknown, with gene-gene and gene-environment interactions not 
considered in genome-wide associated studies (Ober 2016). Further research is necessary 
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to understand the complex nature of these interactions and the genetic influences 
associated with asthma.  
 
1.1.3.2. Environment Exposure 
Asthma exacerbations are often caused by an inflammatory response to an environmental 
trigger such as bacterial and viral infections, allergen exposure, air pollutants and ambient 
air temperature changes (Global Initiative for Asthma 2017). Environmental triggers of 
asthma can act in isolation or in combination. Previous theories were based on specific 
inflammatory mediators associated with trigger types (Singh and Busse 2006). Siegle et 
al. (2010) found the interaction between viral infections and allergen exposures were 
crucial in inducing asthma in murine models. The mechanisms of the interactions between 
viral infections and allergen exposure are not fully understood (Kloepfer and Gern 2010, 
Siegle et al. 2010). These poorly understood trigger mechanisms and interactions 
contribute to substantial heterogeneity in asthma aetiology. This heterogeneity and lack 
of understanding present a challenge in the development of treatment options.  
 
1.1.4. Treatment 
Currently, there is no cure for asthma. Disease management is based on prevention and 
resolution of symptoms. The lack of knowledge on the disease mechanisms of asthma has 
resulted in non-specific treatments that are associated with highly variable responses. As 
highlighted in earlier sections, the multi-factorial and heterogeneous nature of asthma 
poses many challenges for developing more effective management options. The major 
drug classes currently used in the management of acute asthma are: 
 
Beta-2 adrenergic agonists: bronchodilators that activate beta-2 adrenoceptors. This 
inhibits the release of intracellular calcium ions via signalling through cyclic adenosine 
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monophosphate, resulting in smooth muscle relaxation (Johnson 2001). Short-acting 
beta-2 adrenergic agonists are used for the initial treatment of asthma exacerbations. 
Adverse effects include mild tachycardia and tremor (Sears 2002). Resistance is a major 
issue, leading to the need for additional medication (Barisione et al. 2010). 
 
Anticholinergic bronchodilators: bronchodilators that act as antagonists to M muscarinic 
receptors on ASM (Soler and Ramsdell 2014). This prevents acetylcholine binding to M 
receptors and associated bronchoconstriction. Inhaled anticholinergics bronchodilators 
are not used alone, rather typically in conjunction with 𝛽𝛽2 adrenergic agonists. This 
addition is more effective in patients with severe acute asthma exacerbations, suggesting 
acetylcholine may play a bigger role in more severe forms of asthma (Haydel 2017).  
 
Systemic corticosteroids: synthetic analogues of steroid hormones. Glucocorticoids bind 
to glucocorticoid receptors, causing the up-regulation of anti-inflammatory proteins and 
down-regulation of pro-inflammatory proteins and have a plethora of metabolic effects 
(Oakley and Cidlowski 2013). They are extremely effective as an anti-inflammatory agent 
usually initiated within the first hour of an asthma exacerbation at emergency departments 
(EDs). They are most effective as glucocorticoids are key regulators of whole-body 
homeostasis (McKay and John A. Cidlowski 2003). They are used sparingly in children 
due to the wide range of associated adverse effects that include: changes in bone 
metabolism, adrenal suppression, increased skin conditions and multiple deleterious 
psychiatric effects (Poetker and Reh 2010). Cooper et al. (2015) found 88% of asthma 
patients taking oral corticosteroids experienced side effects, which led to a high 




1.1.5. Childhood Asthma 
Asthma most commonly begins in childhood (Croner and Kjellman 1992, Yunginger et 
al. 1992). In Australia, the prevalence of asthma in children is 11% (Australian Bureau 
of Statistics 2015). Accumulated evidence, particularly emphasised by Martinez (2009, 
2011) has strongly correlated persistent asthma with disease progression from childhood. 
Additionally, a longitudinal study from ages 8 to 50 found that 85% of children with 
severe asthma continued to experience symptoms into adulthood, while only 36% of 
children with mild asthma followed the same trend (Tai et al. 2014). Persistent childhood 
asthma that continues into adulthood share environmental triggers and thus potentially 
underlying mechanisms (de Nijs, Venekamp and Bel 2013). Permanent airway 
remodelling may begin in early childhood, which makes it is important to treat asthma 
early to prevent long-term damage, particularly in children with severe forms of asthma. 
 
Conversely, it is equally important to withhold mediations with adverse long-term effects, 
if the disease is known to not persist. This is a major issue in paediatric emergency 
departments with the treatment of severe asthmatic symptoms in children using oral 
corticosteroids (Beigelman, Durrani and Guilbert 2016). Not all children with symptoms 
of acute asthma will have persistent asthma in the future. These children are characterised 
with having wheeze, with associate acute wheeze, wheeze attacks or wheeze 
exacerbations (Brand et al. 2008). The distinguishing characteristic between asthma and 
wheeze is the lack of chronicity, which is only known retrospectively. Wheeze is common 
in young children, with the Tuscon Cohort Study of 1246 newborns finding that 48.5% 
had a wheeze exacerbation before the age of 6 (Martinez et al. 1995). The minimum 
recommended age of diagnosis of asthma stated by GINA is age 6 (Global Initiative for 
Asthma 2017, 14). This minimum age may protect pre-school children from being 
incorrectly diagnosed with asthma. However, this also delays early treatment of pre-
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school children with asthma or wheeze that will persist into asthma. To date, there is still 
a lack of understanding of this disease progression. 
 
1.2. Metabolomics 
Metabolomics is the systematic study of relative metabolite abundance in a biological 
system (Dunn et al. 2010), as a result of genetic and environmental factors at a given time 
(Fiehn 2002). Metabolites are reactants, intermediates, and end products of biochemical 
reactions, typically with a molecular weight (MW) below 1500 Daltons (Dunn et al. 
2011). While metabolites are a sensitive snapshot of a particular biochemistry and/or 
pathophysiology, they are also highly sensitive to analytical variations including, but not 
limited to, storage, temperature and time (Yin, Lehmann and Xu 2015). With these 
variations taken into consideration, understanding the roles of significant metabolites can 
potentially aid in elucidating disease mechanisms and identifying novel therapeutic 
targets (Emwas et al. 2013). Metabolomics studies can be categorised into two main 
approaches: targeted and untargeted.  
 
1.2.1. Metabolomics Approaches 
The targeted approach is a bottom-up strategy characterised by the quantification of a 
defined group of known metabolites (Roberts et al. 2012). Quantification can be made 
with high specificity and sensitivity (Lämmerhofer and Weckwerth 2013). However, a 
priori knowledge is required to determine the metabolites to target.  
 
The untargeted approach is a top-down strategy characterised by the simultaneous 
measurement of a wide range of metabolites (Alonso, Marsal and Julià 2015). It is used 
in metabolomics when there is a lack of a priori knowledge, and thus it is used for 
hypothesis generation. An untargeted approach is used to look at the widest possible range 
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of metabolites, however due to the range of physicochemical properties, one analytical 
platform cannot be used to detect all metabolites (Scalbert et al. 2009). 
 
1.2.2. Analytical Tools 
There is no single analytical platform that can be used to analyse all metabolites in a given 
biological sample. Nuclear magnetic resonance (NMR) spectroscopy and mass 
spectrometry (MS) are the two most widely used analytical methods of detection in 
metabolomics (Dunn et al. 2010). NMR can detect metabolites with robustness and 
reproducibility, but it suffers from relatively low inherent sensitivity with the limit of 
detection at the nanogram level compared to the picogram level with MS (Pan and Raftery 
2007, Villas-Bôas 2007). The greater sensitivity of MS makes it an ideal analytical 
technique for biomarker discovery. 
 
The principle of MS is to detect ions by their mass-to-charge ratio (m/z) and to quantify 
the ions according to their relative abundance. Mass spectrometers are typically used in 
combination with chromatography: gas chromatography (GC) or liquid chromatography 
(LC). This is to enhance resolving power by separating analytes based on their chemical 
properties prior to ionisation in MS (Wixom and Gehrke 2010). In reference to the 
differences in column chemistry and design, GC is generally better suited to separate 
volatile metabolites with low MW, while LC is typically better suited to separate non-
volatile metabolites (Suhre 2012). The benefits of GC coupled to MS for the separation 
of analytes is the reproducibility of elution time. This is used alongside fragmentation 





1.2.2.1. Gas Chromatography  
GC provides analyte separation based on elution. The instrument consists of an injector, 
column and a detector (Figure 1.3). Precise quantities of the sample enter via a syringe 
into the injector. The solvent and sample are vaporised in the injector into a gaseous 
phase. Analytes enter the coiled capillary composed of fused silica coated internally with 
a thin film stationary phase, inside a temperature-controlled oven. Analytes in the gas 
phase are passed through the column via an inert gas, typically helium (Kitson, Larsen 
and McEwen 1996). The separation of analytes is based primarily on their volatility and 









1.2.2.2. Mass Spectrometry  
Mass spectrometers manipulate and detect gas phase ions (Faull et al. 2008). The 
instrument consists of an ion source, mass analyser and ion detector, maintained under 
vacuum. Gas phase samples enter the ion source and are immediately ionised. The most 
common technique for GC-MS is electron ionisation, where analytes are bombarded with 
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an electron beam commonly at a voltage of 70eV (Harrison 1992). In the mass analyser, 
ions are separated by m/z. The ion detector measures the number of ions by the current as 
a function of time. 
 
A quadrupole (Q) mass filter and time of flight (TOF) mass analyser in tandem are useful 
for untargeted metabolomics. The schematic of a MS with a Q-TOF mass analyser is 
shown in Figure 1.4. The combination of both allows a run in either TOF mode or MS/MS 
mode. The TOF mode allows full scan spectra with accurate mass and high resolution, 
with the MS/MS mode in tandem useful for resolving unknown compounds 
(Chernushevich, Loboda and Thomson 2001).   
 
The quadrupole mass filter only allows ions within a specific m/z range to pass through. 
It consists of four parallel rods, where the specific direct current (DC) and radio frequency 
(RF) voltage are applied (Villas-Bôas 2007). The DC and RF voltage chosen determines 
the m/z range. Only ions within the specific m/z range have the required stable oscillation 
to pass through (Ekman 2009). This can be used for MS/MS to only allow an ion with a 
specific m/z to pass through, or for TOF mode by increasing voltage to allow for a full 
MS scan.   
 
The TOF mass analyser separates ions based on the time taken to reach the detector. All 
ions are accelerated to an identical kinetic energy and thus have a specific velocity 
through the TOF tube based on mass and charge of the ion. Lighter ions of the same 
charge will have a higher velocity and ions with a higher charge will have a higher 
velocity. Due to the high resolution, TOF systems can routinely measure a wide range of 




Figure 1.4: Schematic of a mass spectrometer with a quadrupole-time of flight mass 
analyser. Red arrow represents direction of ions. Blue arrow represents the input and 






1.2.3. Pre-Analytical Issues  
Metabolites are a sensitive snapshot of a particular biochemistry and/or pathophysiology 
(Dunn et al. 2010). However, metabolites are also highly sensitive to analytical variation. 
Pre-analytical issues that can alter metabolite abundance include haemolysis, additional 
freeze-thaw cycles and storage temperature. 
 
1.2.3.1. Haemolysis 
Haemolysis is the rupture of erythrocytes, with intracellular components released into the 
serum including metabolites and enzymes. As reviewed by Hernandes, Barbas and 
Dudzik (2017), primary findings on the effects of haemolysis found significant changes 
in lipids, in particular lysophosphatidylcholines. Haemolysis is visually identifiable as 
the colour of serum is bright red as opposed to pale yellow. This is due to increased 
haemoglobin levels. There are numerous factors that can cause haemolysis in blood 
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samples, including the type of syringe, site of puncture, size of bore needle, the use of 
vacuum tubes and proper technique (Heyer et al. 2012). Training and experience are 
critical in reducing the occurrences of haemolysis, however it is not necessarily avoidable.  
 
1.2.3.2. Additional Freeze-Thaw Cycles 
Freezing is a requirement of samples to increase the longevity. Due to the importance of 
some biological samples, they may be refrozen again and used in supplementary studies. 
An untargeted LC-MS study found 4 out of 705 metabolites to be significantly associated 
with freeze-thaw after four freeze-thaw cycles (Yin et al. 2013). Additionally, a targeted 
LC-MS study found that serum metabolites were generally unaffected by one or two 
freeze-thaw cycles (Breier et al. 2014). There are also additional factors that have not 
been considered, including the time spent thawed and the method used. These additional 
factors warrant further investigation of samples that have been previously used and 
refrozen.  
 
1.2.3.3. Storage Temperature 
Freezing is a critical step in sample handling, with storage conditions having a significant 
effect on metabolites. Storage at −80 °C is the current approach taken for long-term 
storage of bio-fluids (Vaught 2006). Yang et al. (2013) reported differences between 
plasma stored at −80 °C for two months and approximately five years. However, Yang et 
al. (2013) only identified five types of metabolites: lysophosphatidylcholines, 
lysophosphoethanolamines, acylcarnitines, serotonin and hypoxanthine. No studies have 
assessed the varying stability of metabolites at −80 °C (Dunn et al. 2011). As such, issues 
regarding the stability of metabolites with long-term storage of frozen samples requires 
additional investigation.  
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1.2.4. Sample Preparation 
Sample preparation is the steps in which the samples are treated prior to instrumental 
analysis. The serum matrix is complex containing low MW metabolites and higher MW 
species including proteins and ribonucleic acids. These higher MW species need to be 
removed, and the metabolites need to be volatile and stable for GC-MS analysis.  
Additionally, steps including the addition of internal standards and quality control (QC) 
samples are for quality assurance and to correct for analytical variation.  
 
1.2.4.1. Addition of Internal Standards 
Internal standards are chemical compounds with similar chemical properties as the 
analytes of interest. They are added to samples, sample blanks and calibration standards. 
This is used for quantification and for the correction of variation during sample 
preparation (Tan, Boudreau and Lévesque 2012). An internal standard is typically added 
to samples during the deproteination step in the crash solution (Dunn et al. 2011).  
 
1.2.4.2. Quality Control Samples 
In untargeted metabolomics QC samples are used to measure analytical precision, and for 
inter- and intra- batch correction via QC-based signal correction algorithms. The use of 
pooled QC samples proposed by Sangster et al. (2006) is routinely used in untargeted 
metabolomic studies. Pooled QC samples are made from small aliquots of all the 
biological samples. In small-scale studies, both the relative standard deviation (RSD) and 
clustering in unsupervised multivariate plots could be used to determine the 
reproducibility and quality of data prior to statistical analysis. With large-scale 
metabolomic studies, pooled QC samples can confirm and be used to adjust for analytical 




Serum and plasma both contain low MW metabolites and high MW species, including 
proteins and ribonucleic acids. Deproteination is the step to remove these high MW 
species. Deproteination chemically denatures proteins through the disruption and 
potential destruction of secondary and tertiary structures causing protein unfolding 
(Lehninger, Cox and Nelson 2013). Metabolites bound to proteins are released, 
improving chromatographic separation and MS analysis (Villas-Bôas 2007). A crash 
solution typically with an organic solvent and internal standard are used, followed by a 
centrifugation step to separate the precipitated protein and the supernatant containing 
metabolites  (Jiye et al. 2005, Dunn et al. 2011). The precipitated protein is discarded and 
the supernatant is used for metabolomics analysis. 
 
1.2.4.4. Lyophilisation 
Lyophilisation or freeze-drying is a purification process that removes the solvent, 
typically water from the sample. Samples are frozen and transferred to the freezer dryer, 
under vacuum. This method combines deep-freezing and dehydration to cause 
sublimation of solvent while avoiding heat (Villas-Bôas 2007). The drying step is 
essential for the removal of water which would hinder the derivatisation of polar 
compounds (Moldoveanu and David 2015). After lyophilisation, samples could 
potentially be stored at 4°C for an additional 3 months before derivatisation (Dunn et al. 
2011). It is generally considered best practice to store at -80°C.  
 
1.2.4.5. Derivatisation 
Derivatisation improves the volatility and thermal stability of metabolites. Volatile 
metabolites are generally non-polar with a low MW. For non-volatile metabolites, 
chemical derivatization can be used to reduce polarity and thus increase volatility. There 
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are three main types of derivatization reactions: acylation, alkylation and silylation. 
Acylation reagents react to highly polar functional groups, alkylation reagents target 
active hydrogens on amines and acidic hydroxyl groups, and silylation reagents react and 
substitute active hydrogens with silyl group such as trimethylsilyl (TMS) (Grob and Barry 
2004). For silylation, N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) is 
commonly used in combination with methoximation. Methoximation, commonly with O-
methoxyamine hydrochloride in pyridine solution, converts aldehyde and ketone groups 
to their methoxime derivatives to stabilise them prior to silylation (Paik and Kim 2004). 
 
1.2.4.6. Calculation of Retention Index 
To compensate for fluctuations in retention time, a retention index is calculated and used 
instead of a retention time. This is based on the elution of a homologous series of                   
n-alkanes added to the sample prior to injection (Dunn et al. 2011). A stable retention 
index allows analyte comparison to spectral libraries. For example, during GC-MS 
instrument maintenance, approximately 10 cm of the column is removed from the inlet 
end. This reduces the retention time of each metabolite while the retention index remains 
constant. Assuming injection, separation and ionisation parameters are kept constant 
(Schauer et al. 2005), confident comparisons to libraries can be made based on retention 
indices. 
 
1.2.5. Data Processing 
Data processing is a vital data handling step in the metabolomic workflow where raw 
mass spectral data is converted to a data matrix with identified metabolites. The data 
processing workflow includes extraction, deconvolution, alignment, correction and 
metabolite identification. Extraction involves the processing of the extraction ion 
chromatogram peaks for every observed mass. Deconvolution involves the construction 
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of a mass spectrum from the associated peaks at a particular retention time window. 
Particularly in complex fluids such as serum, multiple metabolites may co-elute. As such 
the method of deconvolution is the critical step for the correct identification of 
metabolites. There are multiple software tools for deconvolution with various settings and 
algorithms, with no clear standardised approach (Katajamaa and Orešič 2007, Lu et al. 
2008). Alignment is the correction for elution time shifts, particularly common in larger 
studies. Additionally, inter- and intra- batch variation due to technical variation requires 
signal correction in larger studies. The Quality Control- Robust Spline Batch Correction 
(QC-RSC) utilises pooled QC samples at every x injection to adjust for technical variation 
(Kirwan et al. 2013). For untargeted GC-MS metabolite identification, libraries such as 
the National Institute of Standards and Technology mass spectral library (NIST) are a 
useful resource. The library contains thousands of reference spectra with acquisition 
information and retention indices. Metabolite identification using commercial or public 
libraries is putative (Salek et al. 2013).  
 
1.2.6. Metabolomic Studies in Asthma 
A diverse range of metabolites has been found in previous metabolomics studies on 
asthma. A meta-analysis of pathways identified in more than one study is shown in Table 
1.4. Overall, the metabolic pathways that have been identified are associated with central 
energy metabolism alterations (tricarboxylic acid cycle) and immune/inflammatory 
responses. Hypoxia, amino acid metabolism, lipid metabolism and oxidative stress 
represent a metabolic intersection between central energy metabolism and inflammation 
(Kominsky, Campbell and Colgan 2010). Hypoxia signalling is associated with various 
asthma remodelling and inflammatory mechanisms, including the upregulation of 
lymphocyte survival factors and increased inflammatory cell infiltration (Ahmad et al. 
2012). Amino acid metabolites are known to have various pro- and anti- inflammatory 
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effects. Lipid mediators can act as inflammatory signalling molecules and can also cause 
bronchoconstriction via binding to receptors on ASM (Fogarty et al. 2004, Pelaia et al. 
2008). Thus, these are potentially important pathways related to the metabolic disease 
mechanisms of asthma and identifying novel therapeutic targets. 
 
 
Table 1.3: Meta-analysis containing significant metabolite pathways found in multiple 
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Note: 1(Comhair et al. 2015). 2(Chun et al. 2015). 3(Sinha et al. 2012). 4(Jung et al. 
2013). 5(Saude et al. 2011). 6(McGeachie et al. 2015). 7(Mattarucchi, Baraldi and 
Guillou 2012). 8(Caldeira et al. 2012). 9(Montuschi 2009). 10(Ried et al. 2013). 
11(Loureiro et al. 2016). 12(Carraro et al. 2007). 13(Fitzpatrick et al. 2014). 14(Loureiro 
et al. 2014). EBC represents exhaled breath condensate.  
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The two childhood asthma metabolomics studies using blood samples have been reported 
from authors Fitzpatrick et al. (2014) and McGeachie et al. (2015). Fitzpatrick et al. 
(2014) compared mild-to-moderate asthma (n=22) and severe asthma (n=25) and found 
the glycine, serine and threonine metabolism pathway, the N-acylethanolamine and N-
acyltransferase pathway to be significant. This study lacked a control group and thus only 
describes differences between severity phenotypes of childhood asthma. McGeachie et 
al. (2015) used a targeted lipidomics approach on asthma control, comparing usage (n=8) 
and lack of usage (n=12) of short-acting 𝛽𝛽2 agonists within 7 days prior to sampling. No 
significant pathways were associated with asthma control. Owing to the specific target 
aims and lack of control groups, both studies lack the ability to understand underlying 
disease mechanisms.  
 
There is a need for untargeted metabolomics in asthma research to help elucidate 
underlying disease mechanisms before targeting specific pathways. While metabolomics 
is a powerful tool for understanding underlying disease mechanisms, irreproducibility 
arising from biological and analytical sensitivity is a substantial issue. This is further 
compounded by sampling bias, inadequate sample size, inappropriate analyses and over-
fitting (Broadhurst and Kell 2006).  Major issues in current metabolomic studies in 
asthma are the limited sample sizes and lack of findings validation (Amber, Michael and 
Jessica 2015). There is a need for an untargeted standardised method, particularly for 
childhood asthma using larger sample sizes to generate suitable libraries of significant 
metabolites and metabolite pathways.  
 
1.3. The Mechanisms of Acute Viral Illness in Children Study 
The Mechanisms of Acute Viral Illness in Children (MAVRIC) cohort study conducted 
by the University of Western Australia, in collaboration with Princess Margaret Hospital 
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(PMH) and the Telethon Kids Institute (TKI) in Perth. As the name suggests, the broad 
study aim is to investigate viruses causing acute lower respiratory infections, including 
children with asthma exacerbations and wheeze exacerbations. Children were recruited 
soon after a presentation to the emergency department at PMH with an acute lower 
respiratory infection. Serum was collected within 24 hours of presentation and stored at   
-80 °C. Clinical data collected included age, sex, corticosteroid usage and presence of a 
viral infection. The control group in this study comprised of children that were healthy 
children without any respiratory illnesses. Despite its advantages as a cohort, the 
MAVRIC study was not originally designed with metabolomics in mind. Hence, there 
are potentially a number of limiting factors that affect the serum samples used in this 
study, such as storage time of samples (up to 6 years old), number of freeze-thaw cycles 
and haemolysis of blood prior to serum collection that may impact the outcomes of 
metabolomics analyses. 
 
1.4. Research Aims 
Serum samples from the MAVRIC cohort study can be used to uncover significant 
metabolite pathways associated with childhood asthma. As the MAVRIC study was not 
designed specifically for metabolomics studies, it was important to determine the effects 
of potential confounding factors on experimental outcomes. The three main research aims 
were:  
1. To assess the impact of potentially limiting factors of the retrospectively 
collected serum samples on metabolomic analysis. 
2. To determine whether metabolomics can identify potential biomarkers to 
distinguish between acute wheeze/asthma and healthy controls. 
3. To determine whether metabolomics-derived biomarkers can identify 
differences between preschool-aged and school-aged phenotypes.   
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Chapter Two: Materials and Method 
 
2.1. Chemicals and Reagents 
Acetonitrile, ethanol, heptane and methanol of LC-MS grade, and water of HPLC (High 
Performance LC) grade were purchased from Thermo Fisher Scientific (Massachusetts, 
United States of America). Methoxyamine hydrochloride, N-methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA), n-alkanes (C10, C12, C15, C19, C22, C28, C32, and C36), 
pyridine and 13C6-Sorbitol were purchased from Sigma-Aldrich (New South Wales, 
Australia).  
 
2.2. MAVRIC Study Population 
Children were recruited upon presentation to the PMH emergency department with an 
acute lower respiratory infection. Data and bio-fluids were collected within 24 hours 
according to the MAVRIC protocol and stored for later analysis. Data collected included 
items from the child’s medical record and questionnaires that were administered to at 
least one parent. These included emergency department physician discharge diagnosis, 
use of corticosteroids, age and gender. Biofluids collected included serum and nasal fluid. 
The study was approved by the PMH Human Research Ethics Committee, with 
parental/guardian written informed consent obtained prior to participation (Human 
Research Ethics Committee Reference Number: 1761). Emergency department 
physicians evaluated participants in accordance with published international guidelines 
(Reddel et al. 2009) and determined each child’s diagnosis at discharge. Standard hospital 
protocols determined the treatment regimen and included inhalation of salbutamol and 
ipratropium bromide at 20 minute intervals for the first hour, and then oral prednisolone 
at 1 mg/kg (maximum 40 mg) if respiratory symptoms persisted (Hales et al. 2009, 
Subrata et al. 2009). Due to the impact of prednisolone on bone health, children under 3 
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were not given oral corticosteroids. Peripheral blood was collected after initial treatment, 
with the serum stored at -80 °C according to the laboratory protocol. Viral detection on 
nasal specimens from each child was primarily based on direct fluorescent antibody 
testing (Bizzintino et al. 2011). The virus detected were primarily Human Rhinovirus in 
this study. Additionally, healthy children were recruited as controls including siblings 
and children at the PMH emergency department with non-chronic and non-respiratory 
based conditions.  
 
2.3. Metabolomics Study 
For this metabolomics study, 215 individual serum samples from the MAVRIC cohort 
were used (n=164 acute wheeze/asthma diagnosis; n = 51 controls). Samples were 
selected based on the following two criteria: the diagnosis of acute wheeze/asthma by the 
emergency department physician and a minimum volume of 186 uL/mL serum was 
available. Clinical information of the final study population is shown in Table 2.1. Note, 
three samples (from the acute wheeze/asthma diagnosis group) were excluded from the 




Table 2.1: Clinical information of the final study population (n=212). 
 
 
Clinical Information Control Acute Wheeze/Asthma 
Subjects, n 51 161 
Doctor Diagnosed Acute Asthma, 
≥6 years old (%)/ <6 years old (%) 
 
0(0%)/0(0%) 32(20.9%)/47(95.7%) 




Gender ratio, Male/Female 25/36 109/52 
Virus detected ratio, Yes/No 19/29 132/24 
Steroids given ratio, Yes/No 0/51 127/23 
* IQR - interquartile range. 
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2.4. Sample Randomisation 
Randomisation was used to reduce confounding factors in the analytical experimental 
design. Sample order was randomised during the aliquoting, extraction and derivatisation 
steps. As such, final instrumental injector order (identical to sample derivatisation order) 
was primarily based on acute wheeze/asthma or control, and included gender, age, storage 
time, aliquoting order and extraction order. 
 
2.5. Sample Preparation 
2.5.1. Sample Aliquoting 
Minimal volumes were required to be aliquoted from the original serum samples. This is 
due to the importance of the preservation of serum samples for future MAVRIC cohort 
studies and publications. In total, 186 𝜇𝜇L of serum was used for metabolomic analysis.  
 
At TKI, serum samples were left to thaw in the 4 °C fridge for 15 hours. Samples were 
vortexed for 5 seconds and then centrifuged for 10 minutes at 9 520 using a Hettich 
MIKRO 20 centrifuge (Tuttlingen, Germany). Five aliquots of each sample were placed 
in sterile 1.5 mL microcentrifuge tubes (SSIBio, California, United States of America); 
one 20 𝜇𝜇L aliquot for GC-MS analysis and four 30 𝜇𝜇L aliquots for future LC-MS analysis. 
Additionally, 46 𝜇𝜇L of each sample (excluding haemolysed samples) were transferred to 
a sterile 15 mL centrifuge tube (Sigma-Aldrich, New South Wales, Australia) to make 
the pooled QC samples. Following the aliquoting of all biological samples, the pooled 
QC sample was vortexed for 5 seconds, then 20 𝜇𝜇L aliquots for GC-MS analysis and 30 
𝜇𝜇L aliquots for LC-MS analysis were pipetted into sterile 1.5 mL microcentrifuge tubes. 
Samples were then transferred on dry ice to Murdoch University, South Street Campus 
and stored at -80 °C. 
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2.5.2. Metabolite Extraction  
The 20 𝜇𝜇L serum samples for GC-MS analysis were thawed on ice for 30 minutes. Thirty 
microliters of 13C6-sorbitol (internal standard; 5.0𝜇𝜇g/mL) in HPLC-grade water was 
added and followed by 150 𝜇𝜇L of methanol to chemically denature proteins. Samples 
were agitated at 1400 RPM using an Eppendorf Thermomixer Comfort (New South 
Wales, Australia) for 10 minutes at 4 °C, then centrifuged at 16 100 g using an Eppendorf 
5415R centrifuge (New South Wales, Australia) for 4 minutes at 4 °C. Following this, the 
supernatant (150 µL) was transferred to a sterile 1.5 mL microcentrifuge tube and 450 𝜇𝜇L 
HPLC-grade water was added. Samples were vortexed for 10 seconds and 75 𝜇𝜇L was 
transferred to a 100 𝜇𝜇L glass-insert (Thermo Fisher Scientific, Victoria, Australia). The 
100 𝜇𝜇L glass-insert was placed inside another sterile 1.5 mL microcentrifuge tube and 
vacufuged in the Eppendorf Concentrator Plus rotary vacuum concentrator (New South 
Wales, Australia) for 30 minutes to reduce the methanol content. Samples were frozen on 
dry ice and freeze-dried using a Labconco Freezone 2.5 Plus freeze-dryer (Missouri, 
United States of America). After 24 hours, the dried sample extracts were stored at 80 °C 
until derivatisation. 
 
2.5.3. Metabolite Derivatisation 
The dried extracts were treated with 20 µL of methoxyamine hydrochloride in pyridine 
(20 mg/mL). Extracts were agitated for 90 minutes at 30 °C and 1400 rpm using an 
Eppendorf Thermomixer Comfort, then centrifuged for 1 minute at 16 100 g using an 
Eppendorf 5415R centrifuge. MSTFA (40 µL) was then added to the extracts. Samples 
were agitated further for 30 minutes at 75oC and 300 rpm using the Eppendorf 
Thermomixer Comfort. The 100 𝜇𝜇L glass-inserts containing the samples were then 
transferred to 2 mL crimp-top vials (Thermo Fisher Scientific, Victoria, Australia).           
n-alkanes in heptane (5 µL containing 12.5 𝜇𝜇g/mL of C10, C12, C15, C19, C22 and C28; 
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and 25.0 𝜇𝜇g/mL of C32 and C36) were added to the samples. All vials were subsequently 
capped and loaded onto the GC-Q-TOF-MS after 4 hours. The purpose of this 4 hour 
delay was to ensure completion of the derivatisation reactions prior to the first sample 
injection. 
 
2.6. Instrument Analysis 
The Agilent 7200 Accurate-Mass Quadrupole Time-of-Flight GC/MS System (Agilent 
Technologies, California, United States of America) was used for the untargeted 
metabolomic analysis of the derivatised samples. Each derivatisation batch included an 
analytical QC at the start, end and after every fifth injection for both inter- and intra- batch 
correction and to assess analytical precision. Additionally, 3 heptane blanks, 3 
derivatisation blanks, 3 extraction blanks and 8 conditioning QC samples were included 
prior to the run. (Note: heptane blanks contained heptane; derivatisation blanks went 
through the derivatisation process; and extraction blanks went through the entire process 
using 20 µL of HPLC-grade water instead of 20 µL serum). The acquisition sequence 
was run continuously without stops between derivatisation batches.  
 
The method parameters used for GC-MS described below were as per the standard 
Separation Science and Metabolomics Laboratory protocol for untargeted analysis of 
serum using GC-QTOF-MS in electron ionisation mode. Six 8 𝜇𝜇L aliquots of acetonitrile 
were used as solvent washes pre- and post- sample injection, with one 2 𝜇𝜇L sample wash 
just prior to injection. 1 𝜇𝜇L of derivatised sample was injected into the inlet set at 270°C 
in splitless mode, with the carrier gas of ultra-high purity helium at a constant flow rate 
of 0.85 mL/min. The Agilent VF-5-ms fused silica capillary column (0.25 mm ID, 30 m 
length, 0.25 𝜇𝜇m film and 10 m EZ-guard; Agilent Technologies, California, United States 
of America) was used. The chromatographic method was 23.5 minutes long including a 
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10 minute solvent delay. Initial oven temperature was 70 °C. A temperature ramp of 
15°C/min for 6 minutes and 40 seconds was then applied until a final temperature of 
325°C was reached. The transfer line was set at 300°C and the ion source was set to 
280°C. Ionisation was achieved with a 70 eV electron beam. The MS has a scan rate of 
10 spectral scans per second and scanned ion masses in the range of m/z 50 to 700. 
 
2.7. Data Processing 
Raw GC-MS data was converted and imported into Analyzer Pro v5.0 (SpectralWorks, 
Cheshire, England) for data processing. The parameters for all settings are listed in 
Appendix 2. Initially, all analytical QC samples were processed. A target component 
library was made from deconvoluted metabolites found in at least 80% of analytical QC 
samples. All samples were then processed against this target library and the data matrix 
was exported as a comma-separated values file. To correct for inter- and intra- batch 
variation, the QC-RSC algorithm was used (Kirwan et al. 2013). QC samples with 
uncharacteristic variations in peak area associated with non-systematic technical issues 
were removed prior to QC-RSC correction (Section 3.1.2).  
 
2.7.1. Exclusion Criteria  
Erroneous samples and metabolites were removed prior to statistical analysis. Samples 
with >20% missing values were initially removed and Principal Component Analysis 
(PCA) was performed to identify additional erroneous samples (Section 3.1.3).  The RSD 
for the pooled QC samples (RSDQC) and for the biological samples (RSDSample) was 
determined for each feature. Metabolites with >20% missing values, RSDQC >30% or a 
ratio of RSDSample:RSDQC <1.5 were excluded from further analysis as they were not 
sufficiently reproducible (Section 3.1.4). Additionally, features that were identified in the 
extraction and derivatisation blanks were excluded from further analysis (Section 3.1.4). 
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2.7.2.  Metabolite Identification 
Features were putatively identified by the comparison of the mass spectra and retention 
index to the NIST 2011 mass spectral library (v 2.0). Metabolites were identified using 
the previously published parameters of  >700 forward match, >700 reverse match and 
20% probability (Abbiss et al. 2015). Features not identified were named 
Unknown_RetentionTime_RetentionIndex_BasePeak. The list of identified compounds 
used for statistical analysis is shown in the results Table 3.1.  
 
2.8. Statistical Analysis 
The final feature matrix and additional clinical and technical data were combined, in order 
to complete both univariate and multivariate analysis using RStudio (RStudio Inc., 
Massachusetts, United States of America). For univariate analysis, missing values were 
excluded as there was no association (p-value < 0.05) between percent missing across the 
clinical groups using the chi-squared test (Appendix 3).  Spearman’s rank correlation 
coefficient was used to compare feature peak area and storage time. The matrix was      
log-transformed, and a two-way Analysis of variance (ANOVA) was used to compare 
acute wheeze/asthma vs. healthy, pre-school vs. school age and the associated 
interactions. Additionally, adjusted p-values (q-values) to correct for multiple 
comparisons using the Benjamini-Hochberg method was also reported. For multivariate 
analysis, the matrix was log-transformed, scaled to unit variance and missing values were 
imputed using the k-Nearest Neighbour algorithm with k=3. PCA was then used for 






Chapter Three: Results 
 
3.1. Data Cleaning 
3.1.1. Inclusion of Replicate Samples  
There were three biological samples with issues visually identified in their associated 
total ion chromatogram (TIC) during the instrumental analysis. The TICs of AAS304LD 
and 681CA (Figure 3.1a) both showed a high baseline shift and missing peaks. The TIC 
of AAS518CC showed an issue with taller peak heights (Figure 3.2a) and overloading in 
the peak for the internal standard 13C6-sorbitol (Figure 3.2b). As the sample extraction 
process only required 75 𝜇𝜇L of the 600 𝜇𝜇L extraction solution, replicate samples were 
made. Replicate samples of AAS304LD, 681CA and AAS518CC were derivatised and 
injected at the end of the instrumental run in batch 7. The TICs of these replicate samples 
did not share the issues previously described (Figure 3.1b, Figure 3.1c, Figure 3.2b and 




































Figure 3.1: Overlay of the TICs for AAS304LD and 681CA. A; TIC of AAS304LD (blue) and 681CA (green) overlaid on QC9 (black), QC36 (black) 
and QC63 (black). B; TIC of AAS304LD (blue) and replicate AAS304LD (red) overlaid on QC9 (black), QC36 (black) and QC63 (black). C; TIC of 



















    
























    
























          

















Figure 3.2: Overlay of the TIC for AAS518CC. A; TIC of AAS518CC (cyan) overlaid on QC9 (black), QC36 (black) and QC63 (black). B; TIC of 
AAS518CC (cyan) and replicate AAS518CC (pink) overlaid on QC9 (black), QC36 (black) and QC63 (black). C; TIC of AAS518CC (cyan) and replicate 



















    





















































3.1.2. Exclusion of Quality Control Samples 
Analytical QC samples were used for measuring analytical precision, as well as inter- and 
intra- batch correction via QC-based signal correction algorithms. Due to the latter, 
analytical QC samples were critically evaluated with possible exclusion determined prior 
to the finalised batch correction. The TICs of analytical QC samples was overlaid and 
three analytical QC samples (QC10, QC11 and QC51) appeared to be of poor quality 
(Figure 3.3a). At close inspection, the TIC of QC10 showed retention time shifts, 
uncharacteristically tall peak heights as well as additional missing peaks when compared 
to other analytical QC samples (Figure 3.3b). The TIC of QC11 displayed a systemic 
issue with high baseline shift and a majority of missing peaks (Figure 3.3c). This is similar 
to samples AAS304LD and 681CA (Figure 3.1a). The TIC of QC51 showed a reduction 
in the baseline with uncharacteristically small peak heights when compared to other 
analytical QC samples (Figure 3.3d). While these three analytical QC samples were 
identified as potentially erroneous, they were initially included in the first batch 










































Figure 3.3: Overlay of the TICs for QC10, QC11 and QC51. A; TIC of QC10 (orange), QC11 (red) and QC51 (pink) overlaid on QC9 (black), QC36 
(black) and QC63 (black). B; TIC of QC10 (orange) overlaid on QC9 (black), QC36 (black) and QC63 (black). C; TIC of QC11 (red) overlaid on QC9 
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To assess the impact of QC10, QC11 and QC51 on batch correction, before and after 
correction plots of peak area (log-scaled) vs. injection order were produced for each 
metabolite. Figure 3.4 is an example of the effect problem QC samples (QC51) have on 
batch correction. Figure 3.4a (prior to batch correction) showed the general deviation of 
peak areas (log-scaled) within and between batches, and the uncharacteristically low peak 
area for QC51. This low peak area was not shown in samples injected prior to, or after 
QC51. When QC51 was included, the batch correction over-adjusted for this low peak 
area which caused a clear upward drift at the end of batch 5 (Figure 3.4b). When QC51 
was excluded, the clear upward deviation introduced by this over-correction to QC51 was 
removed (Figure 3.4c). Given the chromatographic trends and impacts on QC-based 
signal correction, these identified erroneous QC samples were removed prior to the batch 





















Figure 3.4: Injection order vs. peak area (log-scaled) for Unknown_15.5_1913_147.       
A; prior to QC correction. B; using QC correction, with the inclusion of QC10, QC11 and 
QC51. C; using QC correction, with the exclusion of QC10, QC11 and QC51. Red circle 
indicates QC51. Red arrow indicates the upward trend associated with the batch 





3.1.3. Exclusion of Samples 
As indicated in Section 2.7.1, samples with >20% missing values were excluded. QC10, 
QC11 and QC51 would have been removed if they weren’t previously (as described in 
Section 3.1.2), with 25.7%, 81.4% and 28.4% missing values respectively. Five biological 
samples labelled AAS304LD, 476ET, 626PM, 681CA and 704ZA were removed with 
80.9%, 20.8%, 24.0%, 76.5% and 43.2% missing values respectively (Clinical 
information found in Appendix 4). Note, this included AAS304LD and 681CA with 
issues described in Section 3.1.1, but not their associated replicate samples that had 12.0% 
and 11.5% missing values respectively.  As the samples were retrospectively analysed 
from an existing cohort and the cohort was not specifically designed for metabolomics, 
there were potential problems associated with samples. This included 3 haemolysed 
samples and 2 samples that had been through an additional freeze-thaw cycle compared 
to all other samples. Visual inspection of the PCA score plot was used to determine 
whether the 2 replicate samples, 3 haemolysed samples and 2 samples with an additional 
freeze-thaw should be included or excluded. On inspection of the PCA score plot with all 
these samples, there was no clear variation observed in Principal Component 1 (PC1) or 
Principal Component 2 (PC2) from the rest of the samples, nor was there clustering 
(Figure 3.5). Therefore, there was no clear evidence for the removal of those samples.  
 
Additionally, based on the PCA score plot (Figure 3.6), there were two other potentially 
erroneous samples with a PC1 score less than -15 and greater than 15. The sample with 
the PC1 score less than -15 was identified as AAS518CC, previously described in Section 
3.1.1 as having issues regarding peak heights, thus confirming the exclusion. The sample 
with a PC1 score >15 was identified as AAS327DD. Based on the TIC for this sample, 
there was no clear issue that could explain this score beyond expected biological variation 





Figure 3.5: Principal component score plot of PC1 vs. PC2 for samples after the 
exclusion of AAS304LD, 476ET, 626PM, 681CA and 704ZA (>20% missing values). 
Replicate samples are green. Additional freeze-thaw samples are pink. Haemolysed 






















Figure 3.6: Principal component score plot of PC1 vs. PC2 for samples after the 
exclusion of AAS304LD, 476ET, 626PM, 681CA and 704ZA (>20% missing values). 
AAS518CC is red. AAS518CC replicate is green. AAS327DD is purple. All other 
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3.1.4. Exclusion of Features 
As previously stated (Section 2.7.1), features with >20% missing values, RSDQC >30%, 
or a ratio of RSDSample:RSDQC <1.5 were excluded from further analysis, as they were 
not sufficiently reproducible. One hundred and eighty-three features were initially 
identified and processed as described in Section 2.7. Twenty-three features were excluded 
based on >20% missing values (Appendix 5). Thirty-four features were excluded based 
on RSDQC >30% (Appendix 6). Twenty-three features were then excluded based on a 
ratio of RSDSample:RSDQC <1.5 (Appendix 7). After these exclusion criteria, 103 features 
remained. A number of these were features that were included with no biological 
relevance. Thus, features that were found in the extraction and derivatisation blanks were 
also excluded. As a consequence, 52 features remained since 51 features were found in 
the blanks and were subsequently removed. Of these final 52 features, 24 were putatively 
identified using NIST. The final list of features and the identified metabolites are shown 













Table 3.1: Compound information for final list of metabolites/features. Information from data processing; compound number (based on order of retention 
time), retention time, retention index and base peak. Match criteria (forward match, reverse match, NIST probability and retention index) and CAS 
number was provided from NIST match. RSDQC is also provided. 
 
Compound 



















003 Serine 2TMS Amino acid 10.19 1208 116 886 834 95.5 1158 70125-39-2 26.0 
008 Unknown_10.27_1218_301 Unknown 10.27 1218 301      07.1 
012 Isoleucine 2TMS Amino acid 10.49 1247 158 898 913 69.3 1272 7483-92-3 11.5 
014 Threonine 2TMS Amino acid 10.53 1253 073 920 926 92.5 1193 7536-82-5 14.3 
015 Proline 2TMS Amino acid 10.58 1260 142 911 919 93.5 1258 7364-47-8 15.6 
017 Unknown_10.63_1267_086 Unknown 10.63 1267 086      06.9 
019 Unknown_10.67_1272_129 Unknown 10.67 1272 129      21.0 
032 Serine 3TMS Amino acid 11.05 1323 204 885 892 30.4 1322 64625-17-8 19.2 
035 Unknown_11.13_1333_188 Unknown 11.13 1333 188      23.5 
037 Unknown_11.16_1337_147 Unknown 11.16 1337 147      26.8 
040 Threonine 3TMS Amino acid 11.28 1353 073 907 912 96.4 1357 7537-02-2 16.8 
047 Unknown_11.52_1385_176 Unknown 11.52 1385 176      07.6 
050 Unknown_11.55_1389_243 Unknown 11.55 1389 243      20.6 
053 beta-Alanine 3TMS Amino acid 11.70 1410 248 863 863 93.3 1434 55255-77-1 24.9 
059 Unknown_12.11_1464_155 Unknown 12.11 1464 155      16.7 
060 Succinate 3TMS Carboxylic acid 12.16 1470 073 755 755 63.0 1390 38166-11-9 23.5 
064 meso-Erythritol, 4TMS Polyhydric Alcohol 12.27 1485 073 913 915 37.6 1427 n/a 14.9 
071 Unknown_12.45_1509_084 Unknown 12.45 1509 084      25.6 
072 Unknown_12.50_1516_176 Unknown 12.50 1516 176      22.1 
075 Unknown_12.57_1525_292 Unknown 12.57 1525 292      11.3 
081 Creatinine 3TMS Amino Acid 12.80 1556 115 763 795 48.8 1592 n/a 29.7 
082 Phenylalanine 1TMS Amino Acid 12.85 1562 120 848 854 97.4 1547 2899-42-5 21.1 
083 Unknown_12.87_1564_166  Unknown 12.87 1564 166      26.0 
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085 Unknown_13.04_1587_142 Unknown 13.04 1587 142      28.8 
086 Unknown_13.95_1589_174 Unknown 13.05 1589 174      19.5 
087 Ribofuranose 4TMS  Monosaccharide 13.11 1597 217 781 825 24.7 1671 n/a 13.9 
096 Phenylalanine 2TMS Amino Acid 13.39 1635 218 902 904 81.8 1710 2899-52-7 22.0 
100 Unknown_13.50_1649_073 Unknown 13.50 1649 073      23.3 
102 Unknown_13.62_1664_073  Unknown 13.62 1664 073      18.8 
106 Arabitol 5TMS Polyhydric Alcohol 13.93 1706 073 869 869 23.0 1746 35-21-2 13.7 
109 Arabinofuranose 4TMS Monosaccharide 14.32 1758 217 830 868 24.0 1671 55399-49-0 19.0 
112 Citric acid 4TMS Tricarboxylic Acid 14.69 1808 273 896 896 98.2 1944 14330-97-3 14.6 
113 Ornithine 4TMS Amino acid 14.72 1811 142 817 818 58.6 1702 n/a 25.2 
119 Unknown_15.08_1860_073 Unknown 15.08 1860 073      21.0 
121 Unknown_15.21_1877_059 Unknown 15.21 1877 059      09.8 
122 Unknown_15.36_1897_158 Unknown 15.36 1897 158      11.1 
123 Unknown_15.37_1898_160 Unknown 15.37 1898 160      08.0 
125 Mannitol 6TMS Polyhydric Alcohol 15.42 1905 319 792 806 48.5 2066 14317-07-8  14.4 
130 Unknown_15.64_1941_073 Unknown 15.64 1941 073      27.7 
134 Unknown_16.05_2006_204 Unknown 16.05 2006 204      16.9 
135 Inositol 6TMS Polyhydric Alcohol 16.08 2011 217 780 780 43.3 2194 14251-18-4 18.1 
136 Palmitoleic acid 1TMS Fatty Acid 16.19 2027 117 784 784 68.6 1995 n/a 21.7 
138 Unknown_16.47_2072_204 Unknown 16.47 2072 204      26.1 
139 Myo-Inositol 6TMS Polyhydric Alcohol 16.51 2078 217 922 923 80.5 2194 2582-79-8 12.7 
147 Linoleic acid TMS Fatty Acid 17.35 2212 081 802 805 69.5 2202 56259-07-5 18.0 
148 Tryptophan 3TMS Amino acid 17.39 2220 202 920 930 64.0 2257 55429-28-2 13.8 
157 Unknown_18.26_2387_091 Unknown 18.26 2387 091       21.8 
161 Unknown_18.96_2519_427 Unknown 18.96 2519 427        21.4 
174 Unknown_20.72_2855_221 Unknown 20.72 2855 221      29.2 
178 Gastrodigenin 2TMS Benzyl Alcohol 21.30 2966 221 717 879 67.8 1803 n/a 17.9 
182 Unknown_22.47_3190_329 Unknown 22.47 3190 329      24.3 
183 Unknown_22.47_3190_107 Unknown 22.47 3190 107      05.4 
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3.1.5. Result of Data Cleaning 
The exclusion of sample and feature outliers, and the inter- and intra- batch correction 
were necessary prior to statistical analysis.  This is demonstrated in the PCA score plot 
(PC1 vs. PC2) for the data matrix prior to data cleaning (Figure 3.8). In this initial PCA 
score plot, PC1 explained 13.8% of the variance and PC2 explained 9.7% of the variance. 
Additionally, PC1 clearly showed at least one analytical QC sample outlier, specifically 
with a PC1 value less than -30. There was also a large spread in the analytical QC samples 
in both PC1 and PC2. Following data cleaning, PC1 explained 26.4% of the variance and 
PC2 explained 10.5% of the variance (Figure 3.9). Additionally, there were no clear 
outliers in QC samples with PC1 or PC2. PC1 did not cluster analytical QC samples, 
showing that the variance described in PC1 is mostly associated with technical variation. 
The analytical QC samples were clustered in PC2 with a large spread of biological 















Figure 3.8: Principal component score plot of PC1 vs. PC2 for the data matrix prior to 
the removal of metabolite outliers, feature outliers and inter- and intra- batch correction. 





Figure 3.9: Principal component score plot of PC1 vs. PC2 for the data matrix after the 
removal of metabolite outliers, feature outliers and inter- and intra- batch correction. 














3.2. Statistical Analysis 
3.2.1. Storage Time 
In this study, efforts were made to ensure both the wheeze/asthma exacerbation group 
and the control group were matched for storage time. However, there was a greater range 
of storage time for the wheeze/asthma exacerbation group. The median and interquartile-
range of storage time were 3.8 (2.8-5.2) years for the wheeze/asthma group, and 3.4 (2.9-
4.1) years for the control group. The Spearman’s rank correlation coefficient was used to 
assess the relationship between storage time and peak area (Table 3.3). Seven features 
were found to be significantly (p-value < 0.05) correlated with storage time. Of these,         
4 were identified metabolites including serine (both 2TMS and 3TMS products), 
succinate and tryptophan. While statistically significant, the Spearman’s Rho values were 
















Table 3.2: Spearman’s rank correlation between metabolite abundance and storage time.  
 
Compound 
Number Compound Name 
Spearman's 
Rho p-value q-value 
161 Unknown_18.96_2519_427 0.50 1E-12 8E-11 
102 Unknown_13.62_1664_073  -0.22 0.002 0.04 
060 Succinate 3TMS 0.22 0.003 0.06 
100 Unknown_13.50_1649_073 0.20 0.01 0.08 
003 Serine 2TMS 0.16 0.02 0.19 
032 Serine 3TMS 0.14 0.05 0.37 
148 Tryptophan 3TMS -0.14 0.05 0.37 
113 Ornithine 4TMS 0.12 0.08 0.53 
109 Arabinofuranose 4TMS -0.11 0.10 0.59 
134 Unknown_16.05_2006_204 -0.10 0.16 0.74 
081 Creatinine 3TMS -0.10 0.16 0.74 
136 Palmitoleic acid 1TMS 0.11 0.17 0.74 
015 Proline 2TMS -0.09 0.20 0.81 
112 Citric acid 4TMS -0.09 0.23 0.81 
017 Unknown_10.63_1267_086 -0.08 0.25 0.81 
085 Unknown_13.04_1587_142 -0.08 0.26 0.81 
083 Unknown_12.87_1564_166    -0.08 0.28 0.81 
122 Unknown_15.36_1897_158 -0.08 0.29 0.81 
086 Unknown_13.95_1589_174 -0.07 0.30 0.81 
130 Unknown_15.64_1941_073 -0.07 0.31 0.81 
008 Unknown_10.27_1218_301 -0.07 0.33 0.81 
139 Myo-Inositol 6TMS 0.06 0.36 0.86 
138 Unknown_16.47_2072_204 -0.06 0.38 0.86 
053 beta−Alanine 3ΤΜS 0.06 0.40 0.87 
135 Inositol 6TMS 0.05 0.44 0.88 
019 Unknown_10.67_1272_129 -0.06 0.45 0.88 
157 Unknown_18.26_2387_091 0.05 0.46 0.88 
147 Linoleic acid TMS 0.05 0.49 0.90 
174 Unknown_20.72_2855_221 0.05 0.50 0.90 
106 Arabitol 5TMS -0.05 0.53 0.91 
119 Unknown_15.08_1860_073 -0.04 0.54 0.91 
071 Unknown_12.45_1509_084 0.04 0.56 0.91 
123 Unknown_15.37_1898_160 -0.04 0.61 0.93 
125 Mannitol 6TMS 0.04 0.61 0.93 
047 Unknown_11.52_1385_176 0.03 0.65 0.96 
037 Unknown_11.16_1337_147 0.03 0.69 0.96 
035 Unknown_11.13_1333_188 -0.03 0.70 0.96 
096 Phenylalanine 2TMS 0.03 0.71 0.96 
050 Unknown_11.55_1389_243 0.02 0.79 0.96 
072 Unknown_12.50_1516_176 0.02 0.80 0.96 
059 Unknown_12.11_1464_155 -0.02 0.80 0.96 
082 Phenylalanine 1TMS 0.02 0.81 0.96 
182 Unknown_22.47_3190_329 0.01 0.85 0.96 
014 Threonine 2TMS 0.01 0.85 0.96 
040 Threonine 3TMS 0.01 0.85 0.96 
075 Unknown_12.57_1525_292 -0.01 0.88 0.96 
121 Unknown_15.21_1877_059 0.01 0.88 0.96 
178 Gastrodigenin 2TMS -0.01 0.92 0.96 
087 Ribofuranose 4TMS  0.00 0.95 0.96 
012 Isoleucine 2TMS 0.00 0.96 0.96 
183 Unknown_22.47_3190_107 0.00 0.96 0.96 




3.2.2. Acute Wheeze/Asthma vs. Controls 
The univariate analysis comparing the wheeze/asthma exacerbation group and the 
controls was performed using an ANOVA and median fold-change as previously 
described (Section 2.8). The output of this analysis is shown in Table 3.3. Twenty-nine 
compounds were found to be significantly different (p-value < 0.05) between the 
wheeze/asthma exacerbation group and the control group. Of those 29 features, 14 were 
putatively identified. The amino acids threonine, ornithine, proline, serine, tryptophan 
and isoleucine were decreased in abundance for the wheeze/asthma group compared with 
the control group. There was an increased relative abundance of the monosaccharides 
arabinofuranose and ribofuranose, the polyhydric alcohol mannitol, the carboxylate 








Table 3.3: Two-way ANOVA and median fold-change output. Variable One: wheeze/asthma exacerbation (case) vs. controls. Variable Two: age under 
6 vs. age 6 and over. Q-value: correction for multiple comparisons using the Benjamini and Hochberg Procedure.  
 
Compound 

























040 Threonine 3TMS 0.60 3E-09 2E-07 0.83 0.03 0.20 0.76 0.97 
109 Arabinofuranose 4TMS 1.58 1E-08 4E-07 1.06 0.48 0.74 0.04 0.46 
113 Ornithine 4TMS 0.61 1E-07 2E-06 0.96 0.49 0.74 0.62 0.97 
014 Threonine 2TMS 0.64 2E-07 2E-06 1.08 0.11 0.30 0.91 0.98 
087 Ribofuranose 4TMS  1.41 9E-07 1E-05 1.33 0.17 0.39 0.24 0.89 
138 Unknown_16.47_2072_204 1.58 1E-06 1E-05 1.04 0.57 0.78 0.02 0.46 
037 Unknown_11.16_1337_147 1.40 3E-06 2E-05 1.26 0.003 0.07 0.49 0.97 
015 Proline 2TMS 0.67 7E-06 4E-05 0.94 0.08 0.25 0.11 0.66 
134 Unknown_16.05_2006_204 1.31 8E-06 5E-05 1.25 0.33 0.58 0.03 0.46 
072 Unknown_12.50_1516_176 0.65 1E-04 5E-05 0.84 0.36 0.62 0.97 0.98 
083 Unknown_12.87_1564_166  0.74 2E-04 0.001 1.19 0.30 0.55 0.27 0.89 
019 Unknown_10.67_1272_129 1.35 3E-04 0.001 0.95 0.07 0.24 0.04 0.46 
125 Mannitol 6TMS 2.64 4E-04 0.001 0.88 0.62 0.80 0.96 0.98 
130 Unknown_15.64_1941_073 1.22 4E-04 0.001 0.97 0.15 0.38 0.11 0.66 
071 Unknown_12.45_1509_084 0.79 0.001 0.002 1.04 0.10 0.30 0.34 0.89 
085 Unknown_13.04_1587_142 0.77 0.001 0.002 0.98 0.23 0.46 0.23 0.89 
032 Serine 3TMS 0.84 0.001 0.003 1.02 0.04 0.21 0.73 0.97 
148 Tryptophan 3TMS 0.81 0.002 0.004 1.00 0.64 0.80 0.82 0.97 
060 Succinate 3TMS 1.40 0.002 0.005 1.11 0.72 0.80 0.48 0.97 
003 Serine 2TMS 0.87 0.01 0.01 0.95 0.07 0.24 0.67 0.97 
136 Palmitoleic acid 1TMS 2.05 0.01 0.01 0.75 0.01 0.07 0.57 0.97 
121 Unknown_15.21_1877_059 1.10 0.01 0.01 0.97 0.70 0.80 0.52 0.97 
012 Isoleucine 2TMS 0.91 0.01 0.03 1.35 0.43 0.72 0.64 0.97 
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059 Unknown_12.11_1464_155 0.77 0.02 0.03 1.13 0.69 0.80 0.67 0.97 
157 Unknown_18.26_2387_091 1.22 0.02 0.04 0.93 0.57 0.78 0.76 0.97 
174 Unknown_20.72_2855_221 0.81 0.02 0.04 1.08 0.20 0.44 0.52 0.97 
017 Unknown_10.63_1267_086 0.94 0.02 0.04 0.83 0.90 0.91 0.98 0.98 
147 Linoleic acid TMS 1.29 0.03 0.05 0.81 0.01 0.11 0.81 0.97 
050 Unknown_11.55_1389_243 1.18 0.04 0.08 0.78 0.03 0.20 0.70 0.97 
086 Unknown_13.95_1589_174 1.23 0.05 0.08 0.93 0.24 0.46 0.43 0.97 
106 Arabitol 5TMS 1.11 0.06 0.10 0.91 0.74 0.81 0.46 0.97 
122 Unknown_15.36_1897_158 1.05 0.08 0.14 1.06 0.58 0.78 0.16 0.82 
135 Inositol 6TMS 0.81 0.10 0.16 0.99 0.50 0.74 0.09 0.66 
035 Unknown_11.13_1333_188 0.90 0.14 0.22 1.16 0.01 0.07 0.58 0.97 
008 Unknown_10.27_1218_301 0.91 0.15 0.22 1.02 0.04 0.21 0.55 0.97 
182 Unknown_22.47_3190_329 1.06 0.17 0.24 1.00 0.86 0.89 0.71 0.97 
178 Gastrodigenin 2TMS 0.92 0.19 0.26 1.00 0.23 0.46 0.91 0.98 
119 Unknown_15.08_1860_073 1.07 0.28 0.38 0.62 0.85 0.89 0.05 0.46 
053 beta-Alanine 3TMS 0.92 0.41 0.55 1.07 0.49 0.74 0.93 0.98 
102 Unknown_13.62_1664_073  1.07 0.45 0.59 0.99 0.05 0.24 0.22 0.89 
081 Creatinine 3TMS 1.11 0.50 0.64 1.00 0.05 0.24 0.05 0.46 
064 meso-Erythritol, 4TMS 1.11 0.53 0.65 0.41 0.98 0.98 0.39 0.92 
096 Phenylalanine 2TMS 1.16 0.63 0.76 1.08 0.70 0.80 0.62 0.97 
047 Unknown_11.52_1385_176 1.00 0.66 0.78 0.93 0.17 0.39 0.17 0.83 
183 Unknown_22.47_3190_107 1.00 0.67 0.78 0.75 0.12 0.31 0.88 0.98 
161 Unknown_18.96_2519_427 1.11 0.72 0.81 1.02 0.001 0.06 0.33 0.89 
112 Citric acid 4TMS 1.08 0.80 0.87 0.97 0.07 0.24 0.32 0.89 
139 Myo-Inositol 6TMS 0.97 0.81 0.87 0.64 0.08 0.25 0.29 0.89 
082 Phenylalanine 1TMS 1.07 0.87 0.92 0.90 0.67 0.80 0.97 0.98 
100 Unknown_13.50_1649_073 0.98 0.94 0.96 0.93 0.01 0.07 0.82 0.97 
075 Unknown_12.57_1525_292 1.04 0.95 0.96 1.00 0.53 0.76 0.31 0.89 
123 Unknown_15.37_1898_160 1.00 0.96 0.96 0.99 0.69 0.80 0.37 0.92 
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The wheeze/asthma exacerbation group and the control group were visually compared 
using a PCA (Figure 3.10). PC1 showed no separation of groups.  PC2 showed a variation 
in metabolite profile between the two groups. There was a small spread in PC2 for the 
control group, with a larger spread in PC2 for the wheeze/asthma group. Additionally, 
there was also a small overlap between the wheeze/asthma group and control group 






Figure 3.10: Principal component score plot of PC1 vs. PC2 for all biological samples. 
Acute wheeze/asthma group is coloured red. Control group is coloured blue. 
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3.2.3. Preschool-aged vs. School-aged Acute Wheeze/Asthma 
To determine if there was a difference of acute wheeze/asthma based on age, a two-way 
ANOVA was used as previously described (Section 2.8). The age brackets of less than 6 
years old and greater than (and including) 6 years old were used due to GINA regulations 
on the minimum age (6 years) on asthma diagnosis (Section 1.1.5). The significant 
metabolites were determined by the interaction term of the two-way ANOVA. Five 
features were found to be significantly associated with a p-value less than 0.05 (Table 
3.3). Two were identified as arabinofuranose and creatinine. For arabinofuranose, there 
was a decreased abundance with age for the control group (negative gradient), and 
increased abundance with age for the acute wheeze/asthma group (positive gradient) 
(Figure 3.11). Additionally, there was a difference in metabolite abundance between all 
the groups. For creatinine, the metabolite abundance was similar between the age brackets 
for the acute wheeze/asthma group (0 gradient) (Figure 3.12). For the control group, there 
was a decreased abundance with the ≥6 years old age bracket. Note, unlike in Figure 3.11, 
there is overlap suggesting slight variations in metabolite abundance.   
 
Additionally, through the two-way ANOVA, 10 features were found to be significantly 
associated with the age bracket. Four were identified as serine, threonine, linoleic acid 
and palmitoleic acid (Table 3.3). There was increased relative abundance with the higher 
age bracket for the amino acid serine. There was a decreased relative abundance of the 




Figure 3.11: Plots of peak area (log-scaled) with mean and 95% confidence intervals for 
acute wheeze/asthma vs. control with age bracket for arabinofuranose. Acute 














Figure 3.12: Plots of peak area (log-scaled) with mean and 95% confidence intervals for 
acute wheeze/asthma vs. control with age bracket for creatinine. Acute wheeze/asthma 












The difference between the wheeze/asthma exacerbation group and control group for the 
brackets of less than 6 years old and greater than (and including) 6 years old was visually 
compared using PCA (Figure 3.13). The PCA score plot (PC1 vs. PC2) compared children 
with wheeze/asthma that were less than years old at recruitment, children with 
wheeze/asthma that were greater than (and including) 6 years old, control children that 
were less than years old and control children that were greater than (and including) 6 
years old (Figure 3.11). There is minimal variation found, with no clear distinction to 





Figure 3.13: Principal component score plot of PC1 vs. PC2 for all biological samples. 
Wheeze/asthma exacerbation group; < 6 years old are coloured red and ≥ 6 years old are 
coloured brown. Control group; < 6 years old are coloured blue and ≥ 6 years old are 
coloured green.  
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Chapter Four: Discussion 
 
There were three main aims that this research addressed: to assess the impact of 
potentially limiting factors of retrospectively collected serum samples on metabolomic 
analysis; to determine whether metabolomics can identify potential biomarkers to 
distinguish between wheeze/asthma exacerbation and control groups; and to determine 
whether metabolomics-derived biomarkers can identify differences between preschool-
aged and school-aged phenotypes. The three potentially limiting factors of the samples in 
the study were haemolysis, additional freeze-thaw cycles and storage time. Haemolysis 
and additional freeze-thaw cycles were not found to be significant. Serine, succinate and 
tryptophan abundance was found to be weakly correlated with storage time. Twenty-nine 
metabolites were found to be significantly different (p-value < 0.05) between the acute 
wheeze/asthma group and the control group. Fourteen metabolites were putatively 
identified including amino acids, monosaccharides, fatty acids, a carboxylate and a 
polyhydric alcohol. There was no clear difference on the PCA score plot between the 
acute wheeze/asthma groups based on the age-cut at 6 years (Figure 3.13). However, there 
were five metabolites that were identified as statistically significant, these were 
arabinofuranose and creatinine.  
 
4.1. Potential Limiting Factors of Retrospectively Collected Samples 
4.1.1. Haemolysis 
As haemolysis is the lysis of erythrocytes resulting in the release of intracellular 
components, the release of both metabolites and enzymes was expected to alter the 
abundance of various metabolites. Multiple studies have confirmed that there are 
metabolite abundance variations associated with haemolysis (Denihan et al. 2015, Yin et 
al. 2013, Kamlage et al. 2014). Three of the samples were haemolysed in this study. Due 
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to the small proportion of haemolysed samples, the removal (if required) would result in 
a minimal loss of statistical power. However, there was no clear indication of the need to 
remove these samples (Section 3.1.3). There are two possible explanations that can align 
the findings of this study with that of previous studies and the current understanding of 
asthma; either haemolysis does not affect the metabolites in this study, or the effect on 
the metabolite abundance is minimal. Previous studies have found significant changes 
primarily in lipids which form part of the plasma membrane including 
phosphatidylcholines and lysophsophatidylcholines (Denihan et al. 2015, Yin et al. 
2013). Lipids are not well suited to this untargeted GC-MS analysis given their 
physicochemical properties, with only palmitoleic acid and linoleic acid identified. 
Denihan et al. (2015) found a significant difference in 4 amino acids for haemolysis 
including serine with a minimally associated fold-change of 0.9. This variation in 
metabolite abundance caused by haemolysis may be overshadowed by other factors in 
this study, such as the acute wheeze/asthma. An additional targeted LC-MS analysis is 
needed to analyse the effect of haemolysis on lipids.  
 
4.1.2. Additional Freeze-Thaw Cycle 
Freezing is a requirement of samples to increase their longevity, with samples required to 
be refrozen and thawed for supplementary studies. Two samples in this study went 
through an additional freeze-thaw cycle as they were used in another study of the 
MAVRIC cohort. As a small proportion of samples went through an additional freeze-
thaw cycle, the removal (if required) would have resulted in a minimal loss in statistical 
power. However, there was no clear indication of the need to remove these samples based 
on the PCA score plot (Section 3.1.3). Previous studies on additional freeze-thaw cycles 
support the lack of impact of the additional freeze-thaw cycles (Yin et al. 2013, Breier et 
al. 2014, Anton et al. 2015). However, the reason may be the lack of effect on the specific 
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metabolites identified or the minimal effect on metabolites abundance compared to other 
factors, such as the acute wheeze/asthma. Another issue is the lack of additional 
information regarding the time or method of thawing. Regardless, future LC-MS analysis 
performed on these samples may indicate that the additional freeze-thaw cycle has a 
greater impact on the stability of the metabolites identified.  
 
4.1.3. Storage Time 
There are various studies on the effect of short-term storage (months), however the effects 
of long-term storage (years) on metabolite abundance is limited. One study using 
untargeted LC-MS found a difference in abundance of lysophsophatidylcholines, 
phosphoethanolamines, acylcarnitines, serotonin and hypoxanthine between 2-month and 
5-year batches of plasma from healthy volunteers (Yang et al. 2013). These serum 
samples curated from the MAVRIC cohort were stored between 0.8 and 7.9 years at                
-80°C. The correlation between storage time and metabolite abundance was found to be 
statistically significant (p-value < 0.05) for three metabolites; succinate, serine (2TMS 
and 3TMS) and tryptophan. While statistically significant, the low Spearman’s Rho 
values indicated weak correlations. This suggests that impact of storage time is minimal 
compared to other sources of variation, which in this case is between acute 
wheeze/asthma and the control group. There are no current studies that indicate whether 
there is an impact of long-term storage time on succinate, serine and tryptophan. 
Additionally, the metabolites identified by Yang et al. (2013) were not identified in this 
GC-MS analysis, due to their physicochemical properties. Further LC-MS analysis is 
needed to determine if storage time has a greater effect on lipids. Regardless, the samples 




4.2. Acute Wheeze/Asthma vs. Controls 
Twenty-nine of the 52 metabolites analysed were found to be significantly different                     
(p-value < 0.05) between the acute wheeze/asthma group and the control group. This large 
difference in metabolite profile corresponded to a difference in the spread in the PC2 
shown in the PCA score plot (Section 3.2.2). Fourteen of the 29 metabolites identified 
including the amino acids threonine, ornithine, proline, serine, tryptophan and isoleucine 
were significantly decreased in the acute wheeze/asthma group. Additionally, there was 
a significant increased relative abundance of the monosaccharides arabinofuranose and 
ribofuranose, the polyhydric alcohol mannitol, the carboxylate succinate and the fatty 
acids linoleic acid and palmitoleic acid. 
 
The decreased abundance of serine and threonine levels in acute wheeze/asthma group 
align with a previous study on childhood asthma. In this study, the glycine, serine and 
threonine metabolism pathways were significantly decreased in the severe form of asthma 
(Fitzpatrick et al. 2014). The role of threonine in asthma is not known and there is no 
established role of threonine in inflammation. The decreased abundance of serine may be 
due to the biosynthesis of the antioxidant glutathione, found to be associated with airway 
macrophage functional impairment in severe childhood asthma (Fitzpatrick, Jones and 
Brown 2012). 
 
Ornithine and proline are known to play roles in cell proliferation and collagen synthesis. 
Both have been previously hypothesised to cause airway remodelling and hyper-
responsiveness via synthesis through arginase (Maarsingh, Zaagsma and Meurs 2008). 
Arginase activity has been previously established to be associated with inflammation, as 
the inhibition has been found to prevent air remodelling and inflammation in guinea pig 
models of chronic obstructive pulmonary disease (Pera et al. 2014).  
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Tryptophan metabolism has been linked to multiple disease mechanisms. The important 
pathways of tryptophan include the synthesis of serotonin and kynurenine. Indoleamine 
2,3-dioxygenase, an enzyme in the kynurenine pathway has been implicated in immune 
tolerance and T cell regulation (Meisel et al. 2004, Chen et al. 2016, Bauer et al. 2005). 
However, previous studies on tryptophan, kynurenine or indoleamine 2,3-dioxygenase 
have not shown a significant difference in abundance in asthmatics compared to healthy 
controls (Adkins et al. 2015, van Aalderen 2012). Unlike in this study, previous studies 
have not used samples from children with the acute form of asthma.  
 
There was an increased abundance in the two monosaccharides identified as 
arabinofuranose and ribofuranose. The term furanose is defined as carbohydrates that 
include a five-membered ring with four carbon atoms and one oxygen. Arabinofuranose 
is the furanose form of arabinose, a sugar used as a sweetener. Ribofuranose is the 
furanose form of ribose, synthesised by the body. Ribose is a vital component as 
derivatives are major components of deoxyribonucleic acid, ribonucleic acid, and 
adenosine mono-, di- and tri- phosphates. Additionally, it is noted that ribofuranose can 
be synthesised from arabinofuranose. Decreased levels of arabinose have been reported 
in induced asthma studies in mice (Ho et al. 2013). The decreased levels of arabinose 
could potentially be related to an unidentified biochemical pathway relevant to asthma. 
However, as arabinose is a sweetener, it could also be linked to varying levels of food 
consumption or the current state of fasting in the children.  
 
The polyhydric alcohol mannitol was found to be significantly increased in the acute 
wheeze/asthma group. Polyhydric alcohols such as mannitol are derived from sugars. 
Like arabinose, mannitol is a sweetener so it may also be an indication of the level of 
food consumption or current fasting state. Unlike arabinose, mannitol has been 
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established to induce bronchoconstriction in asthmatics (Romberg, Tufvesson and 
Bjermer 2017, Sverrild et al. 2016). Due to this airway responsiveness to mannitol, 
studies have proposed inhaled mannitol to be a suitable challenge test for asthma when 
spirometry is near normal (White et al. 2016, Parra Pérez et al. 2015). However, there is 
no evidence to suggest that the test was not performed on the children in this study.  
 
Succinate is a key citric acid cycle intermediate produced in the mitochondria. Succinate 
has multiple biological roles, such as an intermediate involved in making adenosine 
triphosphate, and as a signalling molecule in signal transduction, reactive oxygen species 
and hypoxia (Tretter, Patocs and Chinopoulos 2016). Additionally, succinate is linked to 
inflammation as it induces IL-1 beta, an important inflammatory mediator (Tannahill et 
al. 2013). Increased levels of succinate have been found in a previous study in mild 
persistent asthma (Chun et al. 2015). However, as succinate plays multiple roles, more 
information regarding the metabolic pathways are needed.   
 
Linoleic acid and palmitoleic acid were found to be significantly increased in the 
wheeze/asthma exacerbation group. Linoleic acid is an essential fatty acid used in the 
synthesis of arachidonic acid, which is a precursor to some prostaglandins, leukotrienes 
and thromboxane. These are known mediators of both bronchoconstriction and mucosal 
hypersecretion (Section 1.1.2). Additionally, the linoleic acid metabolite known as 13-S-
hydroxyoctadecadienoic acid has been known to drive severe asthma, especially the Th2 
phenotype (Mabalirajan et al. 2013). Palmitoleic acid is an essential fatty acid which is a 
common constituent of glycerides in human adipose tissue. Palmitoleic acid is linked to 
common chronic diseases due to the associated anti-inflammatory properties leading to 
deceased IL-6 and TNF (Souza et al. 2017). The abundance of palmitoleic acid has been 
previously found to be highly correlated with inhaled corticosteroid usage (Reinke et al. 
 64 
2017). All children in this study were on inhaled corticosteroids due to the severity of the 
wheeze/asthma exacerbation, which could explain the high abundance of palmitoleic 
acid. 
 
4.3. Preschool-aged vs. School-aged Acute Wheeze/Asthma 
For this analysis, children were classified based on two age brackets; less than 6 years old 
and greater than (and including) 6 years old. As previously stated, current GINA 
recommendations have set the minimum age for asthma diagnosis at age 6. Five 
metabolites were found to be statistically significant between these two groups when 
accounting for potential age effects (Section 3.2.3). Two of the metabolites were 
identified; creatinine and arabinofuranose. While statistically significant (p-value < 0.05), 
there was no clear metabolite separation in the PCA score plot between the less than 6-
year-old group and the greater than (and including) 6-year-old group with acute 
wheeze/asthma (Figure 3.14). 
 
Arabinofuranose was found to increase with the higher age bracket for the acute 
wheeze/asthma group and decrease for the control group. Additionally, in the lower age 
bracket the abundance of arabinofuranose was higher in the acute wheeze/asthma group. 
Arabinofuranose is the furanose form of arabinose, and as previously stated in Section 
4.2, arabinose has been reported in induced asthma studies in mice (Ho et al. 2013). 
However, as it is a sweetener, it could potentially be indicative of the level of food 
consumption or the current state of fasting in the children. 
 
Creatinine was also found to be statistically significant (p-value < 0.05). In the control 
group, there was a decreased creatinine abundance with age. In the acute wheeze/asthma 
group, there was a similar level of creatinine abundance between the two age brackets. 
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The creatinine abundance of the acute wheeze/asthma group and control group below 6 
years was approximately the same. Creatinine is the breakdown product of creatine 
phosphate which is synthesized in the muscle from arginine, glycine and methionine 
(Brosnan, da Silva and Brosnan 2011). Creatine kinase, which catalyses the conversion 
of creatine, has been shown to be higher in asthmatics (Alberts, Williams and Ramsdell 
1986). Creatine kinase and creatinine levels are related to muscle stress leading to muscle 
damage. This could indicate that ASM stress and/or damage is insignificant in the acute 
wheeze/asthma group under 6, that there is a cumulative and permanent damage 
associated with asthma over time, or that there is a variation in the pathophysiology 
between acute wheeze and acute asthma. 
 
The lack of clear distinction in the PCA score plot may indicate that such age groups are 
arbitrary. This could suggest that wheeze and asthma share the same or similar 
pathophysiology. Alternatively, this could indicate that an age bracket is not suitable. As 
previously mentioned, whether the children have wheeze or asthma (or wheeze that 
develops into asthma) is only known retrospectively (Section 1.1.5). Specific follow up 
studies on the children in this study may prove to be of vital importance as the analysis 
of this data matrix could be based on true wheeze and true asthma. Potentially, 







4.4. General Conclusion  
While the MAVRIC cohort was not designed for metabolomic analysis, there were no 
issues regarding pre-analytical variation that impacted this study. Haemolysis and 
additional freeze-thaw cycles were not found to be significant issues; however, it could 
impact future studies. This could be due to the lack of impact on the types of metabolites 
identified using untargeted GC-MS, or the low level of effect combined with the low 
sample size. Regardless, this suggests that for future studies, these factors would not lead 
to automatic exclusion. The amino acids serine, succinate and tryptophan were found to 
be significantly correlated with storage time. However, the Spearman’s Rho value was 
small, suggesting a minimal impact of storage time compared to other sources of variation 
in metabolite abundance.  This is an important breakthrough that would suggest that other 
bio-banked samples could be used without the major impact of long-term storage time on 
metabolites.  
 
There were issues from the MAVRIC cohort that were discovered through this study. 
These were in regard to the nature of the source of the metabolite abundances of the 
monosaccharides, arabinofuranose and ribofuranose, and the polyhydric alcohol 
mannitol. While they may be related to the pathophysiology of asthma, this cannot be 
assumed. There is the potential that this variation in abundances is directly related to food 
intake or the fasting state of the patient. As such, food intake is a significant factor in this 
metabolomic analysis. This calls for the need for more specific questions to be included 
in questionnaires that can be given to the children who are recruited into the cohort study.  
 
The major finding of this study is that there is a clear differentiation in metabolite profile 
between the wheeze/asthma exacerbation group and the control group. Further research, 
particularly in amino acid and lipid metabolism would be beneficial to improve the 
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understanding of disease mechanisms. Lipids in particular are more readily identified in 
LC-MS analysis and the future untargeted LC-MS analysis on this population may 
uncover vital information regarding the further understanding of the pathophysiology of 
asthma and subsequent novel treatments.  
 
With regards to the age brackets of under 6 years, and over (and including) 6 years for 
the acute wheeze/asthma group, there was little difference in the PCA score plot. 
Arabinofuranose was found to be significant between preschool and school-aged 
wheeze/asthma, however the reason may be in regard to fasting. Creatinine was an 
interesting and unexpected discovery. Creatinine blood tests are readily available and thus 
further analysis on creatinine and the associate pathways may be an important 
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Trends of TMS-derivatised serum metabolites analysed by GCqTOF MS: observations 
from a metabolomics-based childhood asthma study 
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INTRODUCTION 
Asthma is a common, chronic inflammatory disease of the airways which varies widely 
in cause and severity. Asthma attacks are characterised by chest tightness, shortness of 
breath, coughing and wheezing and the underlying pathophysiology for which remains 
unknown. The Mechanisms of Acute Viral Respiratory Infections in Children (MAVRIC) 
study is a cohort study which recruited children upon presentation to the emergency 
department at Princess Margaret Hospital for Children with acute lower respiratory illness 
including wheeze and/or asthma. The aim of the present study was to determine serum 
metabolites which were reproducible over multiple GCqTOF MS acquisition batches 
with a further aim to determine metabolite markers of wheeze/asthma.  
 
METHODS 
The methods used are depicted in Figure 1. Briefly, serum metabolites were extracted and 
in 7 batches and analysed as their TMS derivatives using the Agilent 7200 quadrupole 
time-of-flight GC/MS system without inlet, column or source maintenance. TOF-MS data 
were imported into SpectralWorks’ AnalyzerPro® for deconvolution and untargeted 
processing of the metabolite data. Pooled analytical quality control samples were initially 
processed, with 183 metabolites found in >80% of the samples. All samples were 






Figures 2 and 3 show samples and QC samples before and after QC-RSC correction. After 
applying a quality control-robust spline correction (QC-RSC) algorithm for batch 
correction, fifty-two features had an RSD within the range 5.4 – 29.7%. Twenty-four of 
these features were putatively identified using the National Institute of Standards and 
Technology (NIST v2.0) mass spectral library. Putatively identified features are shown 
in Table 1. 
 
CONCLUSION 
AnalyzerPro provides a robust platform for the visualisation, deconvolution and 
alignment of GC-MS data. Further, AnalyzerPro encompasses a simplified and automated 
identification platform by integrating the NIST Mass Spectral Database for EI GC-MS. 
Of the 52 features deemed reproducible, twenty-four were putatively identified with ease. 
These metabolites are being further investigated for significant differences between the 
wheeze/asthma serum samples and serum from healthy subjects.  
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Setting Corresponding Value 
Minimum Masses 4 
Mass Range 50-700 
Area Threshold 5000 
Height Threshold 0.01% 
Width Threshold 0.01 Minutes 
Tailing 0% 
Signal to Noise 10 
Scan Window 1 
Resolution Minimum 
Smoothing 9 
Retention Index RI File and RI Method 
Target Library Building Retention Time 0.1 Minutes 
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Number Compound Name p-value q-value 
060 Succinate 3TMS 0.10 1.00 
035 Unknown_11.13_1333_188 0.18 1.00 
071 Unknown_12.45_1509_084 0.20 1.00 
014 Threonine 2TMS 0.23 1.00 
123 Unknown_15.37_1898_160 0.31 1.00 
106 Arabitol 5TMS 0.31 1.00 
147 Linoleic acid TMS 0.36 1.00 
085 Unknown_13.04_1587_142 0.36 1.00 
100 Unknown_13.50_1649_073 0.44 1.00 
003 Serine 2TMS 0.53 1.00 
082 Phenylalanine 1TMS 0.54 1.00 
087 Ribofuranose 4TMS  0.62 1.00 
075 Unknown_12.57_1525_292 0.67 1.00 
178 Gastrodigenin 2TMS 0.67 1.00 
059 Unknown_12.11_1464_155 0.69 1.00 
050 Unknown_11.55_1389_243 0.72 1.00 
109 Arabinofuranose 4TMS 0.75 1.00 
161 Unknown_18.96_2519_427 0.77 1.00 
017 Unknown_10.63_1267_086 0.80 1.00 
122 Unknown_15.36_1897_158 0.80 1.00 
138 Unknown_16.47_2072_204 0.81 1.00 
112 Citric acid 4TMS 0.83 1.00 
113 Ornithine 4TMS 0.83 1.00 
053 Beta-Alanine 3TMS 0.87 1.00 
119 Unknown_15.08_1860_073 0.89 1.00 
182 Unknown_22.47_3190_329 0.93 1.00 
157 Unknown_18.26_2387_091 0.98 1.00 
183 Unknown_22.47_3190_107 0.99 1.00 
008 Unknown_10.27_1218_301 1.00 1.00 
015 Proline 2TMS 1.00 1.00 
019 Unknown_10.67_1272_129 1.00 1.00 
032 Serine 3TMS 1.00 1.00 
037 Unknown_11.16_1337_147 1.00 1.00 
040 Threonine 3TMS 1.00 1.00 
047 Unknown_11.52_1385_176 1.00 1.00 
072 Unknown_12.50_1516_176 1.00 1.00 
083 Unknown_12.87_1564_166  1.00 1.00 
086 Unknown_13.95_1589_174 1.00 1.00 
102 Unknown_13.62_1664_073  1.00 1.00 
121 Unknown_15.21_1877_059 1.00 1.00 
125 Mannitol 6TMS 1.00 1.00 
130 Unknown_15.64_1941_073 1.00 1.00 
134 Unknown_16.05_2006_204 1.00 1.00 
135 Inositol 6TMS 1.00 1.00 
136 Palmitoleic acid 1TMS 1.00 1.00 
139 Myo-Inositol 6TMS 1.00 1.00 
148 Tryptophan 3TMS 1.00 1.00 
174 Unknown_20.72_2855_221 1.00 1.00 
012 Isoleucine 2TMS n/a n/a 
064 meso-Erythritol, 4TMS n/a n/a 
081 Creatinine 3TMS n/a n/a 
096 Phenylalanine 2TMS n/a n/a 
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Appendix 4: Clinical Information for the Excluded Samples 
 
 
ID Group Age Gender Diagnosis Viral Steroid Given 
476ET Acute 
wheeze/asthma 






































































Index Base Peak 
% missing 
value 
001 10.05 1189 147 28.5 
006 10.26 1217 147 25.3 
016 10.62 1266 174 20.6 
029 10.97 1313 073 27.4 
031 11.01 1318 245 24.9 
046 11.50 1383 147 20.2 
057 12.07 1458 244 24.2 
062 12.20 1475 073 24.9 
065 12.28 1487 071 29.6 
079 12.79 1554 073 29.6 
094 13.27 1618 355 29.6 
097 13.41 1637 206 59.9 
099 13.45 1642 217 35.0 
107 14.06 1723 277 43.3 
128 15.50 1918 217 41.5 
141 16.69 2107 117 38.6 
150 17.43 2227 357 20.2 
152 17.74 2286 163 40.8 
154 17.80 2298 217 64.6 
156 17.98 2332 188 63.2 
166 19.26 2577 217 39.4 
169 19.62 2645 174 33.2 
171 19.96 2711 361 27.1 
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Index Base Peak RSDqc 
009 10.34 1229 341 33.1 
041 11.32 1359 191 33.1 
045 11.48 1380 242 41.5 
056 11.98 1447 117 31.5 
066 12.32 1492 073 48.9 
073 12.53 1519 069 35.9 
074 12.53 1520 221 31.7 
076 12.63 1533 165 75.9 
088 13.13 1599 239 32.8 
090 13.17 1605 235 47.0 
091 13.21 1611 156 42.9 
093 13.24 1615 246 30.7 
111 14.43 1773 156 61.1 
115 14.85 1829 156 31.4 
116 15.00 1849 117 34.9 
118 15.03 1853 174 51.3 
126 15.44 1908 156 38.6 
129 15.59 1933 218 42.9 
131 15.67 1945 117 44.1 
132 15.82 1968 147 44.4 
140 16.63 2096 221 31.8 
145 17.22 2190 056 55.3 
146 17.24 2193 073 33.2 
153 17.76 2290 073 37.6 
155 17.87 2313 281 30.2 
158 18.39 2412 129 55.5 
160 18.89 2506 221 32.6 
162 19.00 2528 055 57.7 
167 19.45 2613 361 96.8 
168 19.54 2630 221 32.9 
172 20.43 2799 281 31.4 
177 21.10 2928 340 105.7 
180 22.25 3148 237 32.6 















Index Base Peak RSDSample:RSDQC 
004 10.20 1210 179 1.32 
010 10.39 1235 071 1.25 
018 10.65 1269 069 1.44 
021 10.72 1278 213 1.47 
022 10.75 1283 117 1.27 
023 10.76 1284 209 0.99 
024 10.81 1290 069 1.42 
028 10.91 1304 184 1.24 
030 10.99 1315 071 1.35 
036 11.14 1334 073 1.13 
048 11.52 1386 174 1.31 
049 11.53 1387 057 1.11 
052 11.68 1407 184 1.04 
054 11.87 1431 147 1.23 
067 12.36 1498 174 1.44 
068 12.38 1500 057 1.29 
069 12.39 1502 174 1.19 
089 13.15 1602 221 1.23 
105 13.92 1705 282 1.12 
114 14.84 1828 174 1.33 
133 15.98 1994 174 1.36 
164 19.21 2568 149 1.37 















Appendix 8: Missing Values (%), RSDQC and RSDSample:RSDQC for the Final List of Metabolites. 
 
Compound 








Value (%) RSDQC RSDsample:RSDQC 
003 Serine 2TMS Amino acid 10.19 1208 116 01.44 26.0 1.54 
008 Unknown_10.27_1218_301 Unknown 10.27 1218 301 01.81 07.1 2.88 
012 Isoleucine 2TMS Amino acid 10.49 1247 158 00.36 11.5 3.93 
014 Threonine 2TMS Amino acid 10.53 1253 073 03.61 14.3 4.21 
015 Proline 2TMS Amino acid 10.58 1260 142 01.08 15.6 3.73 
017 Unknown_10.63_1267_086 Unknown 10.63 1267 086 06.14 06.9 2.03 
019 Unknown_10.67_1272_129 Unknown 10.67 1272 129 17.33 21.0 2.24 
032 Serine 3TMS Amino acid 11.05 1323 204 04.69 19.2 2.92 
035 Unknown_11.13_1333_188 Unknown 11.13 1333 188 00.72 23.5 3.27 
037 Unknown_11.16_1337_147 Unknown 11.16 1337 147 00.36 26.8 3.05 
040 Threonine 3TMS Amino acid 11.28 1353 073 12.27 16.8 3.36 
047 Unknown_11.52_1385_176 Unknown 11.52 1385 176 04.33 07.6 2.58 
050 Unknown_11.55_1389_243 Unknown 11.55 1389 243 02.89 20.6 6.29 
053 beta-Alanine 3TMS Amino acid 11.70 1410 248 16.61 24.9 2.35 
059 Unknown_12.11_1464_155 Unknown 12.11 1464 155 14.08 16.7 4.19 
060 Succinate 3TMS Carboxylate 12.16 1470 073 02.53 23.5 2.93 
064 meso-Erythritol, 4TMS Polyhydric Alcohol 12.27 1485 073 07.22 14.9 2.13 
071 Unknown_12.45_1509_084 Unknown 12.45 1509 084 00.36 25.6 2.91 
072 Unknown_12.50_1516_176 Unknown 12.50 1516 176 04.33 22.1 7.24 
075 Unknown_12.57_1525_292 Unknown 12.57 1525 292 00.00 11.3 2.37 
081 Creatinine 3TMS Amino Acid 12.80 1556 115 00.36 29.7 2.35 
082 Phenylalanine 1TMS Amino Acid 12.85 1562 120 01.81 21.1 2.32 
083 Unknown_12.87_1564_166  Unknown 12.87 1564 166 02.17 26.0 2.75 
085 Unknown_13.04_1587_142 Unknown 13.04 1587 142 05.05 28.8 2.68 
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086 Unknown_13.95_1589_174 Unknown 13.05 1589 174 11.55 19.5 3.23 
087 Ribofuranose 4TMS  Monosaccharide 13.11 1597 217 00.36 13.9 2.33 
096 Phenylalanine 2TMS Amino Acid 13.39 1635 218 08.30 22.0 5.09 
100 Unknown_13.50_1649_073 Unknown 13.50 1649 073 08.30 23.3 4.59 
102 Unknown_13.62_1664_073  Unknown 13.62 1664 073 14.08 18.8 3.91 
106 Arabitol 5TMS Polyhydric Alcohol 13.93 1706 073 01.81 13.7 3.37 
109 Arabinofuranose 4TMS Monosaccharide 14.32 1758 217 06.14 19.0 2.61 
112 Citric acid 4TMS Tricarboxylic Acid 14.69 1808 273 00.36 14.6 2.67 
113 Ornithine 4TMS Amino acid 14.72 1811 142 09.39 25.2 3.11 
119 Unknown_15.08_1860_073 Unknown 15.08 1860 073 16.25 21.0 1.84 
121 Unknown_15.21_1877_059 Unknown 15.21 1877 059 06.14 09.8 1.70 
122 Unknown_15.36_1897_158 Unknown 15.36 1897 158 03.61 11.1 1.64 
123 Unknown_15.37_1898_160 Unknown 15.37 1898 160 15.52 08.0 10.44 
125 Mannitol 6TMS Polyhydric Alcohol 15.42 1905 319 01.08 14.4 1.73 
130 Unknown_15.64_1941_073 Unknown 15.64 1941 073 00.72 27.7 2.04 
134 Unknown_16.05_2006_204 Unknown 16.05 2006 204 00.72 16.9 2.73 
135 Inositol 6TMS Polyhydric Alcohol 16.08 2011 217 02.17 18.1 4.91 
136 Palmitoleic acid 1TMS Fatty Acid 16.19 2027 117 14.44 21.7 5.07 
138 Unknown_16.47_2072_204 Unknown 16.47 2072 204 09.03 26.1 2.76 
139 Myo-Inositol 6TMS Polyhydric Alcohol 16.51 2078 217 03.97 12.7 2.31 
147 Linoleic acid TMS Fatty Acid 17.35 2212 081 02.17 18.0 3.75 
148 Tryptophan 3TMS Amino acid 17.39 2220 202 01.81 13.8 3.58 
157 Unknown_18.26_2387_091 Unknown 18.26 2387 091 01.44 21.8 2.29 
161 Unknown_18.96_2519_427 Unknown 18.96 2519 427 12.27 21.4 5.44 
174 Unknown_20.72_2855_221 Unknown 20.72 2855 221 00.36 29.2 1.78 
178 Gastrodigenin 2TMS Benzyl Alcohol 21.30 2966 221 07.58 17.9 1.90 
182 Unknown_22.47_3190_329 Unknown 22.47 3190 329 06.14 24.3 2.11 
183 Unknown_22.47_3190_107 Unknown 22.47 3190 107 09.03 05.4 2.02 
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